BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. Hepatology 2000;32:1224-9. [DOI: 10.1053/jhep.2000.20456] [Cited by in Crossref: 546] [Cited by in F6Publishing: 488] [Article Influence: 30.3] [Reference Citation Analysis]
Number Citing Articles
1 Pawlik TM, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl. 2004;10:S74-S80. [PMID: 14762844 DOI: 10.1002/lt.20052] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
2 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 192] [Article Influence: 40.3] [Reference Citation Analysis]
3 Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, Obi S, Kanai F, Kato N, Yoshida H. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int. 2012;32:1434-1442. [PMID: 22712520 DOI: 10.1111/j.1478-3231.2012.02838.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
4 Suh SW, Lee KW, Lee JM, You T, Choi Y, Kim H, Lee HW, Lee JM, Yi NJ, Suh KS. Prediction of aggressiveness in early-stage hepatocellular carcinoma for selection of surgical resection. J Hepatol. 2014;60:1219-1224. [PMID: 24548529 DOI: 10.1016/j.jhep.2014.01.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
5 Utsunomiya T, Shimada M, Hanaoka J, Kanamoto M, Ikemoto T, Morine Y, Imura S, Harada M. Possible utility of MRI using Gd-EOB-DTPA for estimating liver functional reserve. J Gastroenterol. 2012;47:470-476. [PMID: 22170416 DOI: 10.1007/s00535-011-0513-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
6 Miura K, Nagahashi M, Prasoon P, Hirose Y, Kobayashi T, Sakata J, Abe M, Sakimura K, Matsuda Y, Butash AL, Katsuta E, Takabe K, Wakai T. Dysregulation of sphingolipid metabolic enzymes leads to high levels of sphingosine-1-phosphate and ceramide in human hepatocellular carcinoma. Hepatol Res 2021;51:614-26. [PMID: 33586816 DOI: 10.1111/hepr.13625] [Reference Citation Analysis]
7 Zhang X, Wang Y, Li X, Yang A, Li Z, Wang D. The anti-carcinogenesis properties of erianin in the modulation of oxidative stress-mediated apoptosis and immune response in liver cancer. Aging (Albany NY) 2019;11:10284-300. [PMID: 31754081 DOI: 10.18632/aging.102456] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
9 Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, Desai NM, Chapman WC. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg. 2006;203:411-420. [PMID: 17000383 DOI: 10.1016/j.jamcollsurg.2006.06.016] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
10 Lim KC, Wang VW, Siddiqui FJ, Shi L, Chan ES, Oh HC, Tan SB, Chow PK. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology. 2015;61:227-237. [PMID: 24638991 DOI: 10.1002/hep.27135] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
11 Liapi E, Geschwind JF. Chemoembolization for primary and metastatic liver cancer. Cancer J. 2010;156-162. [PMID: 20404613 DOI: 10.1097/ppo.0b013e3181d7e905] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
12 Liu J, Wang K, Yan Z, Xia Y, Li J, Shi L, Zou Q, Wan X, Jiao B, Wang H, Wu M, Zhang Y, Shen F. Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma. PLoS One 2016;11:e0154767. [PMID: 27182739 DOI: 10.1371/journal.pone.0154767] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
13 Zhu P, Zhang B, Wang R, Mei B, Cheng Q, Chen L, Wei G, Xu DF, Yu J, Xiao H, Zhang BX, Chen XP. Selective Inflow Occlusion Technique Versus Intermittent Pringle Maneuver in Hepatectomy for Large Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore). 2015;94:e2250. [PMID: 26683942 DOI: 10.1097/md.0000000000002250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
14 Mizumoto M, Tokuuye K, Sugahara S, Nakayama H, Fukumitsu N, Ohara K, Abei M, Shoda J, Tohno E, Minami M. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008;71:462-467. [PMID: 18243571 DOI: 10.1016/j.ijrobp.2007.09.056] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
15 Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100:376-382. [PMID: 14716774 DOI: 10.1002/cncr.20004] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 5.3] [Reference Citation Analysis]
16 Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol. 2005;23:1839-1846. [PMID: 15774777 DOI: 10.1200/jco.2005.00.620] [Cited by in Crossref: 152] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
17 Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20-29. [PMID: 14681338 DOI: 10.1177/0091270003258669] [Cited by in Crossref: 339] [Cited by in F6Publishing: 323] [Article Influence: 19.9] [Reference Citation Analysis]
18 Tohme S, Geller DA, Cardinal JS, Chen HW, Packiam V, Reddy S, Steel J, Marsh JW, Tsung A. Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma. HPB (Oxford). 2013;15:210-217. [PMID: 23374361 DOI: 10.1111/j.1477-2574.2012.00541.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
19 Blum HE. Treatment of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2005;19:129-45. [DOI: 10.1016/j.bpg.2004.11.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
20 Zheng Z, Liang W, Wang D, Schroder PM, Ju W, Wu L, Zheng Z, Shang Y, Guo Z, He X. Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. Int J Cancer 2015;136:E751-9. [PMID: 25208979 DOI: 10.1002/ijc.29203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
21 Kisaka Y, Hirooka M, Kumagi T, Uehara T, Hiasa Y, Kumano S, Tanaka H, Michitaka K, Horiike N, Mochizuki T, Onji M. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 2006;26:1241-7. [DOI: 10.1111/j.1478-3231.2006.01367.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
22 Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y, Monden M. Report of the 18th follow-up survey of primary liver cancer in Japan: 18th follow-up survey of primary liver cancer. Hepatology Research 2010;40:1043-59. [DOI: 10.1111/j.1872-034x.2010.00731.x] [Cited by in Crossref: 89] [Article Influence: 8.1] [Reference Citation Analysis]
23 Brown DB, Chapman WC, Cook RD, Kerr JR, Gould JE, Pilgram TK, Darcy MD. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol. 2008;190:608-615. [PMID: 18287429 DOI: 10.2214/ajr.07.2879] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann R, Löhe F, Graeb C, Rau H, Schauer R, Jauch K, Caselmann WH, Göke B, Jüngst D. Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. Digestion 2007;75:104-12. [DOI: 10.1159/000104730] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
25 Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 2010;52:63-71. [PMID: 19913935 DOI: 10.1016/j.jhep.2009.10.013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
26 Danta M, Barnes E, Dusheiko G. The surveillance and diagnosis of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2005;17:491-6. [DOI: 10.1097/00042737-200505000-00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
27 Kumar A, Srivastava DN, Bal C. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil. J Vasc Interv Radiol 2006;17:157-61. [PMID: 16415146 DOI: 10.1097/01.rvi.0000195321.20579.f2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol. 2012;47:1152-1159. [PMID: 22438097 DOI: 10.1007/s00535-012-0574-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
29 Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, Kao WY, Huo TI, Huang YH, Su YH. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9:79-86. [PMID: 20831902 DOI: 10.1016/j.cgh.2010.08.018] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 9.6] [Reference Citation Analysis]
30 Hasegawa K, Kokudo N, Shiina S, Tateishi R, Makuuchi M. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: Start of a randomized controlled trial (SURF trial). Hepatol Res. 2010;40:851-852. [PMID: 20649823 DOI: 10.1111/j.1872-034x.2010.00696.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
31 Chow PK. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma. Cancer Treatment Reviews 2005;31:491-5. [DOI: 10.1016/j.ctrv.2005.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Yang MJ, An SY, Moon EJ, Lee MS, Hwang JA, Cheong JY, Won JH, Kim JK, Wang HJ, Cho SW. [Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm]. Korean J Hepatol. 2009;15:474-485. [PMID: 20037266 DOI: 10.3350/kjhep.2009.15.4.474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
33 Imura S, Shimada M, Utsunomiya T. Recent advances in estimating hepatic functional reserve in patients with chronic liver damage. Hepatol Res 2015;45:10-9. [PMID: 24606181 DOI: 10.1111/hepr.12325] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
34 Okada Y, Ina H, Kubota K, Himeno Y, Wakita T, Ohashi I, Gomi N, Yoshida T, Mae S, Irie T. Computed tomography-guided transarterial chemoembolization as the initial therapy for hepatocellular carcinoma: experience of 75 cases in a single institute. Dig Dis Sci 2003;48:587-93. [PMID: 12757174 DOI: 10.1023/a:1022557220624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Korean Society of Abdominal Radiology. Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol 2017;18:427-43. [PMID: 28458595 DOI: 10.3348/kjr.2017.18.3.427] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
36 Cárdenes HR. Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clin Transl Oncol 2009;11:276-83. [DOI: 10.1007/s12094-009-0355-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
37 Raut CP, Izzo F, Marra P, Ellis LM, Vauthey JN, Cremona F, Vallone P, Mastro A, Fornage BD, Curley SA. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12:616-628. [PMID: 15965731 DOI: 10.1245/aso.2005.06.011] [Cited by in Crossref: 121] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
38 Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One 2014;9:e100305. [PMID: 24945380 DOI: 10.1371/journal.pone.0100305] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 9.3] [Reference Citation Analysis]
39 Daocheng W, Mingxi W. Preparation of the core-shell structure adriamycin lipiodol microemulsions and their synergistic anti-tumor effects with diethyldithiocarbamate in vivo. Biomed Pharmacother 2010;64:615-23. [PMID: 20888179 DOI: 10.1016/j.biopha.2010.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag. 2018;14:1157-1168. [PMID: 30013351 DOI: 10.2147/tcrm.s162898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39 Suppl 1:S59-63. [PMID: 14708679 DOI: 10.1016/s0168-8278(03)00140-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
42 França AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res. 2004;37:1689-1705. [PMID: 15517086 DOI: 10.1590/s0100-879x2004001100015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
43 Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Kurokawa T, Nakamura N, Inazawa J, Tanaka H, Arii S. Surgical contribution to recurrence-free survival in patients with macrovascular-invasion-negative hepatocellular carcinoma. J Am Coll Surg 2009;208:368-74. [PMID: 19317998 DOI: 10.1016/j.jamcollsurg.2008.10.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
44 Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018;73:369-85. [DOI: 10.1111/his.13520] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
45 Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev. 2004;CD003046. [PMID: 15106188 DOI: 10.1002/14651858.cd003046.pub3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
46 Corey KE, Pratt DS. Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol. 2009;2:45-57. [PMID: 21180533 DOI: 10.1177/1756283X08100328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
47 Jin YJ, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY, Ahn SI, Shin WY, Cho SG, Jeon YS. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg. 2014;18:555-561. [PMID: 24420729 DOI: 10.1007/s11605-013-2440-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
48 Li MX, Zhao H, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Cai JQ. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. Hepatol Res. 2017;47:731-741. [PMID: 27558521 DOI: 10.1111/hepr.12796] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
49 Inoue K, Takayama T, Higaki T, Watanabe Y, Makuuchi M. Clinical significance of early hepatocellular carcinoma. Liver Transpl 2004;10:S16-9. [DOI: 10.1002/lt.20049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
50 Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Yamamoto M. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology. 2011;54:1273-1281. [PMID: 22006857 DOI: 10.1002/hep.24536] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
51 Seo DD, Lee HC, Jang MK, Min HJ, Kim KM, Lim YS, Chung Y, Lee YS, Suh DJ, Ko G, Lee Y, Lee S. Preoperative Portal Vein Embolization and Surgical Resection in Patients with Hepatocellular Carcinoma and Small Future Liver Remnant Volume: Comparison with Transarterial Chemoembolization. Ann Surg Oncol 2007;14:3501-9. [DOI: 10.1245/s10434-007-9553-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
52 Yang P, Wu D, Xia Y, Li J, Wang K, Yan Z, Shi L, Lau WY, Wu M, Shen F. A prognostic scoring system for patients with multiple hepatocellular carcinomas treated by hepatectomy. Ann Surg Oncol 2015;22:826-33. [PMID: 25216602 DOI: 10.1245/s10434-014-4081-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
53 Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Percutaneous treatment of hepatocellular carcinoma: REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2003;17:103-10. [DOI: 10.1046/j.1365-2036.17.s2.21.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
54 Cai E, Song X, Han M, Yang L, Zhao Y, Li W, Han J, Tu S. Experimental study of the anti-tumour activity and pharmacokinetics of arctigenin and its valine ester derivative. Sci Rep 2018;8:3307. [PMID: 29459629 DOI: 10.1038/s41598-018-21722-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
55 Ripoll C, Genescà J, Araujo IK, Graupera I, Augustin S, Tejedor M, Cirera I, Aracil C, Sala M, Hernandez-guerra M, Llop E, Escorsell A, Catalina MV, Cañete N, Albillos A, Villanueva C, Abraldes JG, Bañares R, Bosch J. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology 2013;58:2079-88. [DOI: 10.1002/hep.26629] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
56 Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: Clinical and biological significance. Hepatology 2013;57:1436-47. [DOI: 10.1002/hep.26122] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
57 Liu PH, Hsu CY, Hsia CY, Lee YH, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2  cm in a Propensity Score Model. Ann Surg 2016;263:538-45. [PMID: 25775062 DOI: 10.1097/SLA.0000000000001178] [Cited by in Crossref: 86] [Cited by in F6Publishing: 46] [Article Influence: 17.2] [Reference Citation Analysis]
58 Berry K, Ioannou GN. Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?: Liver Transplantation for Hepatocellular Carcinoma. American Journal of Transplantation 2012;12:706-17. [DOI: 10.1111/j.1600-6143.2011.03853.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
59 Matsumoto T, Kubota K, Aoki T, Iso Y, Kato M, Shimoda M. Clinical Impact of Anatomical Liver Resection for Hepatocellular Carcinoma with Pathologically Proven Portal Vein Invasion. World J Surg 2016;40:402-11. [PMID: 26306893 DOI: 10.1007/s00268-015-3231-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
60 Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol. 2008;34:333-338. [PMID: 17218078 DOI: 10.1016/j.ejso.2006.12.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
61 Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J, Yamaoka Y, Curley SA, Ellis LM, Nagorney DM. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg. 2003;238:711-719. [PMID: 14578734 DOI: 10.1097/01.sla.0000094436.34556.ac] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
62 Broelsch CE, Frilling A, Malago M. Hepatoma—resection or transplantation. Surgical Clinics of North America 2004;84:495-511. [DOI: 10.1016/j.suc.2003.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
63 Chen J. The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. PLoS One 2018;13:e0200909. [PMID: 30102707 DOI: 10.1371/journal.pone.0200909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, Takehara T. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma-A retrospective multicenter study: PegIFN/RBV Therapy After HCC Treatment. J Med Virol 2015;87:1199-206. [DOI: 10.1002/jmv.24173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
65 Harnois DM. Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma. Mayo Clin Proc. 2012;87:7-8. [PMID: 22212962 DOI: 10.1016/j.mayocp.2011.11.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
66 Mahnken AH, Bruners P, Günther RW. Techniques of interventional tumor therapy. Dtsch Arztebl Int 2008;105:646-53. [PMID: 19471636 DOI: 10.3238/arztebl.2008.0646] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
67 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1] [Cited by in Crossref: 3112] [Cited by in F6Publishing: 1033] [Article Influence: 163.8] [Reference Citation Analysis]
68 Taniguchi M, Kim SR, Imoto S, Ikawa H, Ando K, Mita K, Fuki S, Sasase N, Matsuoka T, Kudo M. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol. 2008;14:1997-2002. [PMID: 18395898 DOI: 10.3748/wjg.14.1997] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
69 Yamada S, Shimada M, Morine Y, Imura S, Ikemoto T, Saito Y, Takasu C, Yoshikawa M, Teraoku H, Yoshimoto T. A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging. PLoS One. 2019;14:e0210579. [PMID: 30682046 DOI: 10.1371/journal.pone.0210579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
70 Mori Y, Tamai H, Shingaki N, Moribata K, Shiraki T, Deguchi H, Ueda K, Enomoto S, Magari H, Inoue I. Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma. Hepatol Int. 2009;3:509-515. [PMID: 19669252 DOI: 10.1007/s12072-009-9131-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
71 Kanwal F, Befeler A, Chari RS, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, Schwartz J. Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network. Aliment Pharmacol Ther. 2012;36:257-265. [PMID: 22670798 DOI: 10.1111/j.1365-2036.2012.05174.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
72 Cong WM, Wu MC. Small hepatocellular carcinoma: current and future approaches. Hepatol Int. 2013;7:805-812. [PMID: 26201917 DOI: 10.1007/s12072-013-9454-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
73 Xieraili M, Yasen M, Mogushi K, Obulhasim G, Mayinuer A, Aihara A, Tanaka S, Mizushima H, Tanaka H, Arii S. Villin 1 is a predictive factor for the recurrence of high serum alpha-fetoprotein-associated hepatocellular carcinoma after hepatectomy. Cancer Sci. 2012;103:1493-1501. [PMID: 22530999 DOI: 10.1111/j.1349-7006.2012.02315.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
74 Hironori K, Masaru T, Yuichiro O, Akira T, Toshio K, Tetsuya M, Mitsunori U, Sumito T. Laparoscopy-assisted hepatectomy for giant hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech 2008;18:127-31. [PMID: 18288006 DOI: 10.1097/SLE.0b013e318158237b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
75 Zhang X, Wang M, Teng S, Wang D, Li X, Wang X, Liao W, Wang D. Indolyl-chalcone derivatives induce hepatocellular carcinoma cells apoptosis through oxidative stress related mitochondrial pathway in vitro and in vivo. Chemico-Biological Interactions 2018;293:61-9. [DOI: 10.1016/j.cbi.2018.07.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
76 Takamoto T, Sugawara Y, Hashimoto T, Makuuchi M. Evaluating the current surgical strategies for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:341-57. [PMID: 26558422 DOI: 10.1586/17474124.2016.1116381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
77 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
78 Abe T, Saitoh J, Kobayashi D, Shibuya K, Koyama Y, Shimada H, Shirai K, Ohno T, Nakano T. Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma. Radiat Oncol. 2015;10:187. [PMID: 26377092 DOI: 10.1186/s13014-015-0491-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
79 Yang Z, Yang Y, Zhou G, Luo Y, Yang W, Zhou Y, Yang J. The Prediction of Survival in Hepatocellular Carcinoma Based on A Four Long Non-coding RNAs Expression Signature. J Cancer 2020;11:4132-44. [PMID: 32368296 DOI: 10.7150/jca.40621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Manzini G, Henne-Bruns D, Porzsolt F, Kremer M. Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? BMJ Open Gastroenterol. 2017;4:e000129. [PMID: 28405349 DOI: 10.1136/bmjgast-2016-000129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
81 Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology. 2004;127:1714-1723. [PMID: 15578509 DOI: 10.1053/j.gastro.2004.09.003] [Cited by in Crossref: 445] [Cited by in F6Publishing: 375] [Article Influence: 27.8] [Reference Citation Analysis]
82 Hirashita T, Ohta M, Iwashita Y, Iwaki K, Uchida H, Yada K, Matsumoto T, Kitano S. Risk factors of liver failure after right-sided hepatectomy. The American Journal of Surgery 2013;206:374-9. [DOI: 10.1016/j.amjsurg.2012.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
83 Osada S, Saji S, Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol 2004;85:48-54. [DOI: 10.1002/jso.20006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
84 Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, Liu QX, Luo JJ, Liu LX, Liu R, Qian S. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer. 2012;12:263. [PMID: 22721173 DOI: 10.1186/1471-2407-12-263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
85 Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report. Oncol Lett 2015;9:2495-8. [PMID: 26137096 DOI: 10.3892/ol.2015.3115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Müller C, Schöniger-hekele M, Schernthaner R, Renner B, Peck-radosavljevic M, Brichta A, Wrba F, Posch M, Bauer P, Ferenci P, Gangl A. Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial. Wien Klin Wochenschr 2008;120:608-18. [DOI: 10.1007/s00508-008-1086-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
87 Hasegawa K, Kokudo N, Sano K, Makuuchi M. Single HCC between 2 and 5 cm: the grey zone: surgeon's perspective. J Hepatobiliary Pancreat Sci 2010;17:430-3. [PMID: 19890599 DOI: 10.1007/s00534-009-0245-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 Zhu G, Sun M, Liao W, Yu W, Zhou S, Zhou Z, Shi Y, Fan J, Zhou J, Qiu L, Dai Z. Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. Expert Review of Gastroenterology & Hepatology 2018;12:935-45. [DOI: 10.1080/17474124.2018.1503531] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
89 Yoshitake K, Tanaka S, Mogushi K, Aihara A, Murakata A, Matsumura S, Mitsunori Y, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S. Importin-α1 as a novel prognostic target for hepatocellular carcinoma. Ann Surg Oncol 2011;18:2093-103. [PMID: 21286940 DOI: 10.1245/s10434-011-1569-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
90 Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl. 2004;10:S46-S52. [PMID: 14762839 DOI: 10.1002/lt.20044] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 6.0] [Reference Citation Analysis]
91 Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102-107. [PMID: 15213625 DOI: 10.1097/01.sla.0000129672.51886.44] [Cited by in Crossref: 178] [Cited by in F6Publishing: 152] [Article Influence: 10.5] [Reference Citation Analysis]
92 Kabilova TO, Kovtonyuk LV, Zonov EV, Ryabchikova EI, Popova NA, Nikolin VP, Kaledin VI, Zenkova MA, Vlassov VV, Chernolovskaya EL. Immunotherapy of hepatocellular carcinoma with small double-stranded RNA. BMC Cancer 2014;14:338. [PMID: 24886485 DOI: 10.1186/1471-2407-14-338] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
93 Li MX, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao H, Cai JQ. Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015;94:e2133. [PMID: 26656342 DOI: 10.1097/MD.0000000000002133] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
94 Chen L, Shi Y, Jiang CY, Wei LX, Wang YL, Dai GH. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg Oncol 2011;37:513-20. [PMID: 21324414 DOI: 10.1016/j.ejso.2011.01.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
95 Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg. 2007;204:1-6. [PMID: 17189106 DOI: 10.1016/j.jamcollsurg.2006.10.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 3.7] [Reference Citation Analysis]
96 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
97 Zhang XY, Li C, Wen TF, Yan LN, Li B, Yang JY, Wang WT, Jiang L. Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A case-control study. World J Gastroenterol. 2015;21:2358-2366. [PMID: 25741142 DOI: 10.3748/wjg.v21.i8.2358] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
98 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
99 Chang AY, Wang M. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC Cancer 2013;13:267. [PMID: 23721490 DOI: 10.1186/1471-2407-13-267] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
100 Sherman M, Takayama Y. Screening and treatment for hepatocellular carcinoma. Gastroenterology Clinics of North America 2004;33:671-91. [DOI: 10.1016/j.gtc.2004.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
101 Herman JM, Pawlik TM. Hepatocellular Carcinoma, Gallbladder Cancer, and Cholangiocarcinoma. In: Lu JJ, Brady LW, editors. Radiation Oncology. Berlin: Springer Berlin Heidelberg; 2008. pp. 221-43. [DOI: 10.1007/978-3-540-77385-6_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Wen X, Jiang X, Li R, Zhang J, Yang P, Shen B. Novel X-Ray Imaging Technology Allows Substantial Patient Radiation Reduction without Image Quality Impairment in Repetitive Transarterial Chemoembolization for Hepatocellular Carcinoma. Academic Radiology 2015;22:1361-7. [DOI: 10.1016/j.acra.2015.07.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
103 Russell MC. Complications following hepatectomy. Surg Oncol Clin N Am. 2015;24:73-96. [PMID: 25444470 DOI: 10.1016/j.soc.2014.09.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
104 Song J, Wang Y, Teng M, Zhang S, Yin M, Lu J, Liu Y, Lee RJ, Wang D, Teng L. Cordyceps militaris induces tumor cell death via the caspase‑dependent mitochondrial pathway in HepG2 and MCF‑7 cells. Mol Med Rep 2016;13:5132-40. [PMID: 27109250 DOI: 10.3892/mmr.2016.5175] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
105 Shindoh J, Hashimoto M, Watanabe G. Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol. 2015;7:70-77. [PMID: 25624998 DOI: 10.4254/wjh.v7.i1.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
106 Maluccio M, Covey AM, Gandhi R, Gonen M, Getrajdman GI, Brody LA, Fong Y, Jarnagin W, D'angelica M, Blumgart L, Dematteo R, Brown KT. Comparison of Survival Rates after Bland Arterial Embolization and Ablation Versus Surgical Resection for Treating Solitary Hepatocellular Carcinoma up to 7 cm. Journal of Vascular and Interventional Radiology 2005;16:955-61. [DOI: 10.1097/01.rvi.0000161377.33557.20] [Cited by in Crossref: 61] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
107 Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011;34:37-49. [PMID: 21069333 DOI: 10.1007/s00270-010-0012-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 7.0] [Reference Citation Analysis]
108 Kaneko H, Takagi S, Otsuka Y, Tsuchiya M, Tamura A, Katagiri T, Maeda T, Shiba T. Laparoscopic liver resection of hepatocellular carcinoma. Am J Surg. 2005;189:190-194. [PMID: 15720988 DOI: 10.1016/j.amjsurg.2004.09.010] [Cited by in Crossref: 238] [Cited by in F6Publishing: 215] [Article Influence: 14.9] [Reference Citation Analysis]
109 Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. Clin Drug Investig. 2012;32 Suppl 2:37-51. [PMID: 22873626 DOI: 10.2165/1163024-s0-000000000-00000] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Nathan H, Mentha G, Marques HP, Capussotti L, Majno P, Aldrighetti L, Pulitano C, Rubbia-Brandt L, Russolillo N, Philosophe B, Barroso E, Ferrero A, Schulick RD, Choti MA, Pawlik TM. Comparative performances of staging systems for early hepatocellular carcinoma. HPB (Oxford) 2009;11:382-90. [PMID: 19768142 DOI: 10.1111/j.1477-2574.2009.00070.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
111 Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC, Choi D, Lim HK, Lee KW, Joh JW. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol. 2005;39:247-252. [PMID: 15718869 DOI: 10.1097/01.mcg.0000152746.72149.31] [Cited by in Crossref: 181] [Cited by in F6Publishing: 160] [Article Influence: 11.3] [Reference Citation Analysis]
112 Thoppil RJ, Bishayee A. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World J Hepatol 2011;3:228-49. [PMID: 21969877 DOI: 10.4254/wjh.v3.i9.228] [Cited by in Crossref: 146] [Cited by in F6Publishing: 106] [Article Influence: 14.6] [Reference Citation Analysis]
113 Gunji T, Kawauchi N, Akahane M, Watanabe K, Kanamori H, Ohnishi S. Treatment of Unresectable Hepatocellular Carcinoma Less Than 2 Centimeters by Transcatheter Arterial Chemoembolization With Autologous Blood Clot: . Journal of Clinical Gastroenterology 2003;36:347-51. [DOI: 10.1097/00004836-200304000-00013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
114 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 45] [Article Influence: 12.9] [Reference Citation Analysis]
115 Xia BW, Zhang YC, Wang J, Ding FH, He XD. Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2015;39:458-68. [DOI: 10.1016/j.clinre.2014.12.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
116 Deng H, Shang W, Lu G, Guo P, Ai T, Fang C, Tian J. Targeted and Multifunctional Technology for Identification between Hepatocellular Carcinoma and Liver Cirrhosis. ACS Appl Mater Interfaces 2019;11:14526-37. [PMID: 30776888 DOI: 10.1021/acsami.8b20600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
117 Yu Y, Lang Q, Chen Z, Li B, Yu C, Zhu D, Zhai X, Ling C. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer. 2009;115:5132-5138. [PMID: 19672999 DOI: 10.1002/cncr.24567] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
118 Sapisochin G, Castells L, Dopazo C, Bilbao I, Minguez B, Lázaro JL, Allende H, Balsells J, Caralt M, Charco R. Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. Ann Surg Oncol. 2013;20:1194-1202. [PMID: 22965574 DOI: 10.1245/s10434-012-2655-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
119 Kuroda S, Tashiro H, Kobayashi T, Oshita A, Amano H, Ohdan H. Selection criteria for hepatectomy in patients with hepatocellular carcinoma classified as Child-Pugh class B. World J Surg. 2011;35:834-841. [PMID: 21190110 DOI: 10.1007/s00268-010-0929-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
120 Franssen B, Jibara G, Tabrizian P, Schwartz ME, Roayaie S. Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB (Oxford) 2014;16:830-5. [PMID: 24372853 DOI: 10.1111/hpb.12206] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
121 Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg. 2008;12:1521-1526. [PMID: 18592325 DOI: 10.1007/s11605-008-0553-4] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
122 Ikushima I, Higashi S, Seguchi K, Ishii A, Ota Y, Shima M, Kanemaru M, Hidaka Y. Transarterial infusion chemotherapy with epirubicin in water-in-oil-in-water emulsion for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Eur J Radiol 2009;69:114-9. [PMID: 17935921 DOI: 10.1016/j.ejrad.2007.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
123 Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary & Pancreatic Diseases International 2011;10:234-42. [DOI: 10.1016/s1499-3872(11)60039-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
124 Kamohara Y, Haraguchi N, Mimori K, Tanaka F, Inoue H, Mori M, Kanematsu T. The search for cancer stem cells in hepatocellular carcinoma. Surgery. 2008;144:119-124. [PMID: 18656616 DOI: 10.1016/j.surg.2008.04.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
125 Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N, An X, Yu J, Li H, Ren X. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34:194-203. [PMID: 24337625 DOI: 10.1007/s10875-013-9976-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 6.5] [Reference Citation Analysis]
126 Bester L, Meteling B, Boshell D, Saxena A, Morris DL. Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer. Hepat Oncol 2014;1:215-28. [PMID: 30190956 DOI: 10.2217/hep.13.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
127 Kim JW, Seong J, Lee IJ, Woo JY, Han KH. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget. 2016;7:40756-40766. [PMID: 27213593 DOI: 10.18632/oncotarget.9450] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
128 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328. [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8.] [Reference Citation Analysis]
129 Lencioni R, Llovet JM. Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead? J Hepatol. 2005;43:377-380. [PMID: 16005537 DOI: 10.1016/j.jhep.2005.06.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
130 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
131 Nouso K, Matsumoto E, Kobayashi Y, Nakamura S, Tanaka H, Osawa T, Ikeda H, Araki Y, Sakaguchi K, Shiratori Y. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol. 2008;23:453-458. [PMID: 17725599 DOI: 10.1111/j.1440-1746.2007.05120.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
132 Ariizumi S, Katagiri S, Katsuragawa H, Kotera Y, Yamamoto M. Sectionectomy Is Suitable for Patients with T2 Hepatocellular Carcinoma according to the Modified International Union against Cancer TNM Classification. Dig Surg 2007;24:342-8. [DOI: 10.1159/000107714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
133 Gory I, Fink M, Bell S, Gow P, Nicoll A, Knight V, Dev A, Rode A, Bailey M, Cheung W. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scand J Gastroenterol. 2015;50:567-576. [PMID: 25615260 DOI: 10.3109/00365521.2014.953572] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
134 Rathod S, Koul R, Bashir B, Chowdhury A, Dubey A. Role of Stereotactic Body Radiation Therapy in Early Stage Small Cell Lung Cancer in the Era of Lung Cancer Screening: A Systematic Review. American Journal of Clinical Oncology 2019;42:123-30. [DOI: 10.1097/coc.0000000000000489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
135 Wei CY, Chau GY, Chen PH, Liu CA, Huang YH, Huo TI, Hou MC, Lin HC, Su YH, Wu JC, Su CW. A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Sci Rep 2020;10:17259. [PMID: 33057213 DOI: 10.1038/s41598-020-74424-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
136 Li Z, Hao D, Jiao D, Zhang W, Han X. Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures. Acad Radiol 2020:S1076-6332(20)30518-3. [PMID: 33060007 DOI: 10.1016/j.acra.2020.08.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
137 Sakata J, Shirai Y, Wakai T, Kaneko K, Hatakeyama K. Long-term outcomes after hepatectomy for recurrences after prior local ablation for hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2008;34:433-8. [DOI: 10.1016/j.ejso.2007.03.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Kamiyama T, Yokoo H, Kakisaka T, Orimo T, Wakayama K, Kamachi H, Tsuruga Y, Yamashita K, Shimamura T, Todo S, Taketomi A. Multiplication of alpha-fetoprotein and protein induced by vitamin K absence-II is a powerful predictor of prognosis and recurrence in hepatocellular carcinoma patients after a hepatectomy. Hepatol Res 2015;45:E21-31. [PMID: 25382703 DOI: 10.1111/hepr.12451] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
139 Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastro 2004;7:431-41. [DOI: 10.1007/s11938-004-0002-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
140 Amano H, Tashiro H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Itamoto T, Asahara T, Ohdan H. Significance of Platelet Count in the Outcomes of Hepatectomized Patients with Hepatocellular Carcinoma Exceeding the Milan Criteria. J Gastrointest Surg 2011;15:1173-81. [DOI: 10.1007/s11605-011-1538-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
141 Yu LH, Yu WL, Zhao T, Wu MC, Fu XH, Zhang YJ. Post-operative delayed elevation of ALT correlates with early death in patients with HBV-related hepatocellular carcinoma and Post-hepatectomy Liver Failure. HPB (Oxford) 2018;20:321-6. [PMID: 29373299 DOI: 10.1016/j.hpb.2017.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
142 Hiraoka A, Hirooka M, Ochi H, Koizumi Y, Shimizu Y, Shiraishi A, Yamago H, Tanihira T, Miyata H, Ninomiya T, Kawasaki H, Ishimaru Y, Sogabe I, Inoue T, Abe M, Hiasa Y, Matsuura B, Onji M, Michitaka K. Importance of screening for synchronous malignant neoplasms in patients with hepatocellular carcinoma: Impact of FDG PET/CT. Liver Int. 2013;33:1085-1091. [PMID: 23601196 DOI: 10.1111/liv.12161] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
143 Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, Guglielmi A. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol. 2004;10:1137-1140. [PMID: 15069713 DOI: 10.3748/wjg.v10.i8.1137] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 89] [Article Influence: 5.7] [Reference Citation Analysis]
144 Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75-84. [PMID: 15645408 DOI: 10.1016/s1542-3565(04)00443-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
145 Su CM, Chou CC, Yang TH, Lin YJ. Comparison of anatomic and non-anatomic resections for very early-stage hepatocellular carcinoma: The importance of surgical resection margin width in non-anatomic resection. Surg Oncol 2021;36:15-22. [PMID: 33276259 DOI: 10.1016/j.suronc.2020.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
146 Jin YJ, Lee SH, Cho SG, Kim JH, Lee JW, Lee KY, Shin WY. Prediction of postoperative liver failure using gadoxetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:1349-56. [PMID: 26916616 DOI: 10.1111/jgh.13327] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
147 Onoe T, Yamaguchi M, Irei T, Ishiyama K, Sudo T, Hadano N, Kojima M, Kubota H, Ide R, Tazawa H, Shimizu W, Suzuki T, Shimizu Y, Hinoi T, Tashiro H. Feasibility and efficacy of repeat laparoscopic liver resection for recurrent hepatocellular carcinoma. Surg Endosc 2020;34:4574-81. [PMID: 31853630 DOI: 10.1007/s00464-019-07246-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Hansen PD, Cassera MA, Wolf RF. Ablative technologies for hepatocellular, cholangiocarcinoma, and metastatic colorectal cancer of the liver. Surg Oncol Clin N Am 2015;24:97-119. [PMID: 25444471 DOI: 10.1016/j.soc.2014.09.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
149 Hasegawa K, Aoki T, Ishizawa T, Kaneko J, Sakamoto Y, Sugawara Y, Kokudo N. Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma. Ann Surg Oncol 2014;21 Suppl 3:S348-55. [PMID: 24566865 DOI: 10.1245/s10434-014-3585-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
150 Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 2007;37:676-691. [PMID: 17617112 DOI: 10.1111/j.1872-034x.2007.00119.x] [Cited by in Crossref: 282] [Cited by in F6Publishing: 109] [Article Influence: 28.2] [Reference Citation Analysis]
151 Sun X, Zhang Y, Lyu N, Li X, Chen M, Zhao M. The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up? Med Sci Monit 2019;25:4941-51. [PMID: 31270311 DOI: 10.12659/MSM.916451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Fang T, Xiao J, Zhang Y, Hu H, Zhu Y, Cheng Y. Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. Quant Imaging Med Surg 2021;11:2837-60. [PMID: 34079746 DOI: 10.21037/qims-20-173] [Reference Citation Analysis]
153 Sucandy I, Cheek S, Golas BJ, Tsung A, Geller DA, Marsh JW. Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors. HPB (Oxford). 2016;18:756-763. [PMID: 27593593 DOI: 10.1016/j.hpb.2016.06.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
154 Takayasu K, Muramatsu Y, Mizuguchi Y, Moriyama N, Okusaka T. Multiple non-tumorous arterioportal shunts due to chronic liver disease mimicking hepatocellular carcinoma: outcomes and the associated elevation of alpha-fetoprotein. J Gastroenterol Hepatol. 2006;21:288-294. [PMID: 16460488 DOI: 10.1111/j.1440-1746.2006.04170.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
155 Qiao G, Cucchetti A, Li J, Cescon M, Ercolani G, Liu G, Pinna AD, Li L, Shen F, Ren J. Applying of pretreatment extent of disease system in patients with hepatocellular carcinoma after curative partial hepatectomy. Oncotarget 2016;7:30408-19. [PMID: 27007152 DOI: 10.18632/oncotarget.8149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
156 Casaril A, Abu Hilal M, Harb A, Campagnaro T, Mansueto G, Nicoli N. The safety of radiofrequency thermal ablation in the treatment of liver malignancies. Eur J Surg Oncol. 2008;34:668-672. [PMID: 17681717 DOI: 10.1016/j.ejso.2007.05.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
157 Wang D, Lu J, Liu Y, Meng Q, Xie J, Wang Z, Teng L. Liquiritigenin induces tumor cell death through mitogen-activated protein kinase- (MPAKs-) mediated pathway in hepatocellular carcinoma cells. Biomed Res Int 2014;2014:965316. [PMID: 24738081 DOI: 10.1155/2014/965316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
158 Kamiyama T, Yokoo H, Furukawa J, Kurogochi M, Togashi T, Miura N, Nakanishi K, Kamachi H, Kakisaka T, Tsuruga Y. Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology. 2013;57:2314-2325. [PMID: 23322672 DOI: 10.1002/hep.26262] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
159 Kuroda S, Kobayashi T, Tashiro H, Onoe T, Oshita A, Abe T, Kohashi T, Oishi K, Ohmori I, Imaoka Y, Tanaka J, Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology. A multicenter randomized controlled trial comparing administration of antithrombin III after liver resection (HiSCO-05 trial). Surgery 2021:S0039-6060(21)00318-4. [PMID: 33926704 DOI: 10.1016/j.surg.2021.03.057] [Reference Citation Analysis]
160 Ikegami T, Shimada M, Imura S, Yoshizumi T, Arakawa Y, Tokunaga T, Morine Y, Kanemura H. The timing of liver transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Milan criteria. Transplantation. 2008;86:641-646. [PMID: 18791443 DOI: 10.1097/tp.0b013e3181814de2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
161 Nagaoka S, Itano S, Ishibashi M, Torimura T, Baba K, Akiyoshi J, Kurogi J, Matsugaki S, Inoue K, Tajiri N, Takada A, Ando E, Kuromatsu R, Kaida H, Kurogi M, Koga H, Kumashiro R, Hayabuchi N, Kojiro M, Sata M. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 2006;26:781-8. [DOI: 10.1111/j.1478-3231.2006.01296.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
162 Marrero JA, Pelletier S. Hepatocellular Carcinoma. Clinics in Liver Disease 2006;10:339-51. [DOI: 10.1016/j.cld.2006.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
163 Lee JE, Jang JY, Jeong SW, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Jin SY, Choi DL. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol. 2012;18:2979-2987. [PMID: 22736922 DOI: 10.3748/wjg.v18.i23.2979] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
164 Itoh S, Morita K, Ueda S, Sugimachi K, Yamashita Y, Gion T, Fukuzawa K, Wakasugi K, Taketomi A, Maehara Y. Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Ann Surg Oncol. 2009;16:3299-3307. [PMID: 19826875 DOI: 10.1245/s10434-009-0721-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
165 Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: retrospective study from HCV-endemic areas. World J Surg. 2006;30:1567-1578. [PMID: 16855807 DOI: 10.1007/s00268-005-0249-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
166 Sherman M. Screening for hepatocellular carcinoma. Hepatology Research 2007;37:S152-65. [DOI: 10.1111/j.1872-034x.2007.00180.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
167 Yamazaki O, Matsuyama M, Horii K, Kanazawa A, Shimizu S, Uenishi T, Ogawa M, Tamamori Y, Kawai S, Nakazawa K, Otani H, Murase J, Mikami S, Higaki I, Arimoto Y, Hanba H. Comparison of the outcomes between anatomical resection and limited resection for single hepatocellular carcinomas no larger than 5 cm in diameter: a single-center study. J Hepatobiliary Pancreat Sci 2010;17:349-58. [PMID: 20464566 DOI: 10.1007/s00534-009-0253-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
168 Hata M, Tokuuye K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Ohara K, Matsuzaki Y, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2005;104:794-801. [PMID: 15981284 DOI: 10.1002/cncr.21237] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
169 Kamiyama T, Orimo T, Wakayama K, Shimada S, Nagatsu A, Yokoo H, Kamachi H, Yamashita K, Shimamura T, Taketomi A. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification. World J Surg Oncol 2017;15:156. [PMID: 28830473 DOI: 10.1186/s12957-017-1229-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
170 de Rosamel L, Blanc JF. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2017;22:175-90. [PMID: 28604110 DOI: 10.1080/14728214.2017.1336538] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
171 Iwata H, Shibamoto Y, Hashizume C, Mori Y, Kobayashi T, Hayashi N, Kosaki K, Ishikawa T, Kuzuya T, Utsunomiya S. Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding efficacy and toxicity. Technol Cancer Res Treat 2010;9:619-27. [PMID: 21070084 DOI: 10.1177/153303461000900610] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
172 Ramacciato G, Mercantini P, Petrucciani N, Ravaioli M, Cucchetti A, Del Gaudio M, Cescon M, Ziparo V, Pinna AD. Does Surgical Resection Have a Role in the Treatment of Large or Multinodular Hepatocellular Carcinoma? The American Surgeon 2010;76:1189-97. [DOI: 10.1177/000313481007601116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
173 Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1343-1350. [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
174 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 91] [Article Influence: 2.4] [Reference Citation Analysis]
175 Chau GY, Lui WY, King KL, Wu CW. Evaluation of effect of hemihepatic vascular occlusion and the Pringle maneuver during hepatic resection for patients with hepatocellular carcinoma and impaired liver function. World J Surg. 2005;29:1374-1383. [PMID: 16240064 DOI: 10.1007/s00268-005-7766-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
176 Jin YJ, Lee JW. Therapeutic priorities for solitary large hepatocellular carcinoma in a hepatitis B virus endemic area; an analysis of a nationwide cancer registry database. J Surg Oncol 2017;115:407-16. [PMID: 28008620 DOI: 10.1002/jso.24519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
177 Hirooka M, Ochi H, Koizumi Y, Tokumoto Y, Hiraoka A, Kumagi T, Abe M, Tanaka H, Hiasa Y. Local recurrence of hepatocellular carcinoma in the tumor blood drainage area following radiofrequency ablation. Mol Clin Oncol 2014;2:182-6. [PMID: 24649330 DOI: 10.3892/mco.2013.229] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
178 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 801] [Cited by in F6Publishing: 736] [Article Influence: 42.2] [Reference Citation Analysis]
179 Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol. 2011;Epub ahead of print. [PMID: 21976133 DOI: 10.1007/s00535-011-0475-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
180 Hu BS, Chen K, Tan HM, Ding XM, Tan JW. Comparison of laparoscopic vs open liver lobectomy (segmentectomy) for hepatocellular carcinoma. World J Gastroenterol. 2011;17:4725-4728. [PMID: 22180716 DOI: 10.3748/wjg.v17.i42.4725] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
181 Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, Mehrabi A, Fonouni H, Bechstein WO, Golling M. Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis. Clin Transplant 2009;23 Suppl 21:61-7. [PMID: 19930318 DOI: 10.1111/j.1399-0012.2009.01111.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
182 Tanaka S, Arii S. Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2010;17:413-419. [PMID: 19941009 DOI: 10.1007/s00534-009-0238-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
183 Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, Benjamin MS, Sherman M, Gallinger S, Burnett B. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol). 2006;18:684-692. [PMID: 17100154 DOI: 10.1016/j.clon.2006.07.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
184 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3778] [Article Influence: 256.5] [Reference Citation Analysis]
185 Fan H, Zhou C, Yan J, Meng W, Zhang W. Treatment of solitary hepatocellular carcinoma up to 2 cm: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20321. [PMID: 32501978 DOI: 10.1097/MD.0000000000020321] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Farinati F, Sergio A, Baldan A, Giacomin A, Di Nolfo MA, Del Poggio P, Benvegnu L, Rapaccini G, Zoli M, Borzio F. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer. 2009;9:33. [PMID: 19171074 DOI: 10.1186/1471-2407-9-33] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
187 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i13.3164] [Reference Citation Analysis]
188 Nuzzo G, Giuliante F, Gauzolino R, Vellone M, Ardito F, Giovannini I. Liver resections for hepatocellular carcinoma in chronic liver disease: experience in an Italian centre. Eur J Surg Oncol 2007;33:1014-8. [PMID: 17207957 DOI: 10.1016/j.ejso.2006.11.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
189 Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-88. [DOI: 10.1053/j.gastro.2004.09.032] [Cited by in Crossref: 369] [Cited by in F6Publishing: 324] [Article Influence: 21.7] [Reference Citation Analysis]
190 Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLoS One 2013;8:e83627. [PMID: 24391798 DOI: 10.1371/journal.pone.0083627] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
191 Vasuri F, Malvi D, Rosini F, Baldin P, Fiorentino M, Paccapelo A, Ercolani G, Pinna AD, Golfieri R, Morselli-Labate AM, Grigioni WF, D'Errico-Grigioni A. Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. World J Gastroenterol 2014;20:13538-45. [PMID: 25309084 DOI: 10.3748/wjg.v20.i37.13538] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
192 Inoue K, Nakamura T, Kinoshita T, Konishi M, Nakagohri T, Oda T, Takahashi S, Gotohda N, Hayashi T, Nawano S. Volume reduction surgery for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:362-366. [PMID: 15034789 DOI: 10.1007/s00432-004-0566-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
193 Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol. 2002;35:S138-S142. [PMID: 12394217 DOI: 10.1097/00004836-200211002-00010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
194 Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009;252:905-13. [PMID: 19567647 DOI: 10.1148/radiol.2523081676] [Cited by in Crossref: 154] [Cited by in F6Publishing: 140] [Article Influence: 12.8] [Reference Citation Analysis]
195 Wang S, Yang Y, Sun L, Qiao G, Song Y, Liu B. Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:2021-2030. [PMID: 32210570 DOI: 10.2147/ott.s232453] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
196 Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, Mannucci PM; Study Group of the Association of Italian Hemophilia Centers. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003;102:78-82. [PMID: 12649165 DOI: 10.1182/blood-2002-10-3310] [Cited by in Crossref: 76] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
197 Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A, Nagorney DM, Belghiti J, Cherqui D, Poon RT, Kokudo N, Vauthey JN. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2013;20:1223-1229. [PMID: 23179993 DOI: 10.1245/s10434-012-2739-y] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 8.9] [Reference Citation Analysis]
198 Tumanova UN, Shchegolev AI. Vascularization of hepatocellular carcinoma. Arkh patol 2015;77:50. [DOI: 10.17116/patol201577250-55] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Ferrero A, Viganò L, Polastri R, Ribero D, Tesoriere RL, Muratore A, Capussotti L. Hepatectomy as Treatment of Choice for Hepatocellular Carcinoma in Elderly Cirrhotic Patients. World J Surg 2005;29:1101-5. [DOI: 10.1007/s00268-005-7768-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
200 Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am. 2010;90:803-816. [PMID: 20637949 DOI: 10.1016/j.suc.2010.04.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
201 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1249] [Article Influence: 170.9] [Reference Citation Analysis]
202 Shimozawa N, Hanazaki K. Longterm prognosis after hepatic resection for small hepatocellular carcinoma. J Am Coll Surg. 2004;198:356-365. [PMID: 14992736 DOI: 10.1016/j.jamcollsurg.2003.10.017] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 5.2] [Reference Citation Analysis]
203 Yamamoto M, Takasaki K, Otsubo T, Saito A, Nakano M. Extent of resection for hepatocellular carcinoma 2 cm or less in greatest diameter. The American Journal of Surgery 2002;184:437-40. [DOI: 10.1016/s0002-9610(02)01005-x] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
204 Yumoto Y, Yagi T, Sato S, Nouso K, Kobayashi Y, Ohmoto M, Yumoto E, Nagaya I, Nakatsukasa H. Preoperative estimation of remnant hepatic function using fusion images obtained by (99m)Tc-labelled galactosyl-human serum albumin liver scintigraphy and computed tomography. Br J Surg. 2010;97:934-944. [PMID: 20474004 DOI: 10.1002/bjs.7025] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
205 Cha C. Surgical Therapy for Hepatocellular Carcinoma: Formulating a Rational Approach. Journal of Clinical Gastroenterology 2013;47:S30-6. [DOI: 10.1097/mcg.0b013e31829440bd] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
206 Lin SM, Chu CM. Percutaneous tumor ablation or surgical resection for small hepatocellular carcinoma? J Gastroenterol Hepatol 2007;22:1561-4. [PMID: 17845682 DOI: 10.1111/j.1440-1746.2007.05116.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
207 Kang YJ, Lee BC, Kim JK, Yim NY, Kim HO, Cho SB, Jeong YY. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2020;43:55-64. [PMID: 31646378 DOI: 10.1007/s00270-019-02349-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
208 Zhang G, Li R, Zhao X, Meng S, Ye J, Zhao L. Validation of the American Joint Committee on Cancer eighth edition staging system in patients undergoing hepatectomy for hepatocellular carcinoma: a US population-based study. J Surg Res 2018;222:55-68. [PMID: 29273376 DOI: 10.1016/j.jss.2017.09.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
209 Arciero CA, Sigurdson ER. Liver-directed therapies for patients with primary liver cancer and hepatic metastases. Curr Treat Options Oncol. 2006;7:399-409. [PMID: 16904057 DOI: 10.1007/s11864-006-0008-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
210 Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg. 2009;198:39-45. [PMID: 19178896 DOI: 10.1016/j.amjsurg.2008.07.051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
211 Wagnetz U, Atri M, Massey C, Wei AC, Metser U. Intraoperative Ultrasound of the Liver in Primary and Secondary Hepatic Malignancies: Comparison With Preoperative 1.5-T MRI and 64-MDCT. American Journal of Roentgenology 2011;196:562-8. [DOI: 10.2214/ajr.10.4729] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 2.9] [Reference Citation Analysis]
212 Sugimoto K, Moriyasu F, Shiraishi J, Yamada M, Imai Y. A phantom study comparing ultrasound-guided liver tumor puncture using new real-time 3D ultrasound and conventional 2D ultrasound. AJR Am J Roentgenol 2011;196:W753-7. [PMID: 21606264 DOI: 10.2214/AJR.10.5552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
213 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 177] [Article Influence: 16.5] [Reference Citation Analysis]
214 Nakayama H, Sugahara S, Fukuda K, Abei M, Shoda J, Sakurai H, Tsuboi K, Matsuzaki Y, Tokuuye K. Proton Beam Therapy for Hepatocellular Carcinoma Located Adjacent to the Alimentary Tract. International Journal of Radiation Oncology*Biology*Physics 2011;80:992-5. [DOI: 10.1016/j.ijrobp.2010.03.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
215 Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848-854. [PMID: 25450201 DOI: 10.1016/j.jhep.2014.11.005] [Cited by in Crossref: 117] [Cited by in F6Publishing: 120] [Article Influence: 16.7] [Reference Citation Analysis]
216 Chen YC, Teng W, Hsieh YC, Chen WT, Jeng WJ, Huang CH, Lin CC, Chen YC, Lin SM, Lin CY, Sheen IS. Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. J Formos Med Assoc 2019;118:1239-46. [PMID: 30581103 DOI: 10.1016/j.jfma.2018.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
217 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 156] [Article Influence: 33.4] [Reference Citation Analysis]
218 Xuan D, Wen W, Xu D, Jin T. Survival comparison between radiofrequency ablation and surgical resection for patients with small hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24585. [PMID: 33607788 DOI: 10.1097/MD.0000000000024585] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Han K, Lee JT, Seong J. Treatment of non-resectable hepatocellular carcinoma: Non-resectable HCC. Journal of Gastroenterology and Hepatology 2002;17:S424-7. [DOI: 10.1046/j.1440-1746.17.s3.39.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
220 Yin Z, Jin H, Ma T, Zhou Y, Yu M, Jian Z. A meta-analysis of long-term survival outcomes between surgical resection and radiofrequency ablation in patients with single hepatocellular carcinoma ≤ 2 cm (BCLC very early stage). Int J Surg 2018;56:61-7. [PMID: 29723677 DOI: 10.1016/j.ijsu.2018.04.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
221 Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ohkawa A. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:e529-e535. [PMID: 22284041 DOI: 10.1016/j.ijrobp.2011.05.056] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
222 Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: A reasonable strategy? Ann Surg. 2003;238:508-18; discussion 518-9. [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44] [Cited by in Crossref: 66] [Cited by in F6Publishing: 129] [Article Influence: 3.7] [Reference Citation Analysis]
223 Bedossa P, Paradis V. Hepatocellular Carcinoma. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 489-501. [DOI: 10.1016/b978-0-443-06803-4.00035-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
224 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
225 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, Nouso K, Kariyama K, Ishikawa T, Hirooka M, Hiasa Y. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. Cancer Sci. 2017;108:1414-1420. [PMID: 28406546 DOI: 10.1111/cas.13257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
226 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 227] [Article Influence: 21.1] [Reference Citation Analysis]
227 Masuda T, Beppu T, Okabe H, Nitta H, Imai K, Hayashi H, Chikamoto A, Yamamoto K, Ikeshima S, Kuramoto M, Shimada S, Baba H. Predictive factors of pathological vascular invasion in hepatocellular carcinoma within 3 cm and three nodules without radiological vascular invasion. Hepatol Res 2016;46:985-91. [PMID: 26670198 DOI: 10.1111/hepr.12637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
228 Li JK, Liu XH, Cui H, Xie XH. Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis. Mol Clin Oncol 2020;12:15-22. [PMID: 31814972 DOI: 10.3892/mco.2019.1941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
229 Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist. 2005;10:269-281. [PMID: 15821247 DOI: 10.1634/theoncologist.10-4-269] [Cited by in Crossref: 85] [Cited by in F6Publishing: 72] [Article Influence: 5.3] [Reference Citation Analysis]
230 Hata M, Tokuuye K, Sugahara S, Tohno E, Nakayama H, Fukumitsu N, Mizumoto M, Abei M, Shoda J, Minami M, Akine Y. Proton Beam Therapy for Aged Patients With Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2007;69:805-12. [DOI: 10.1016/j.ijrobp.2007.04.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
231 Esmaeilzadeh M, Majlesara A, Faridar A, Hafezi M, Hong B, Esmaeilnia-Shirvani H, Neyazi B, Mehrabi A, Nakamura M. Brain metastasis from gastrointestinal cancers: a systematic review. Int J Clin Pract 2014;68:890-9. [PMID: 24666726 DOI: 10.1111/ijcp.12395] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
232 Wada H, Nagano H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Sakon M, Wakasa K, Monden M. Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-α combination therapy following hepatic resection. J Gastroenterol 2007;42:501-6. [DOI: 10.1007/s00535-007-2028-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
233 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
234 Kamiyama T, Kakisaka T, Orimo T, Wakayama K. Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus. World J Hepatol. 2017;9:1296-1304. [PMID: 29359012 DOI: 10.4254/wjh.v9.i36.1296] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
235 Morise Z. Developments and perspectives of laparoscopic liver resection in the treatment of hepatocellular carcinoma. Surg Today 2019;49:649-55. [PMID: 30649611 DOI: 10.1007/s00595-019-1765-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
236 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
237 Teramoto K, Kawamura T, Takamatsu S, Noguchi N, Nakamura N, Arii S. Laparoscopic and thoracoscopic partial hepatectomy for hepatocellular carcinoma. World J Surg 2003;27:1131-6. [PMID: 12917768 DOI: 10.1007/s00268-003-6936-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
238 Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Yamashita K, Taniguchi M, Shimamura T, Matsushita M, Todo S. Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg. 2010;211:443-449. [PMID: 20822741 DOI: 10.1016/j.jamcollsurg.2010.06.005] [Cited by in Crossref: 118] [Cited by in F6Publishing: 98] [Article Influence: 10.7] [Reference Citation Analysis]
239 Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008;49:589-594. [PMID: 18620773 DOI: 10.1016/j.jhep.2008.05.018] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 9.5] [Reference Citation Analysis]
240 Mulcahy MF. Management of hepatocellular cancer. Curr Treat Options Oncol. 2005;6:423-435. [PMID: 16107245 DOI: 10.1007/s11864-005-0045-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
241 Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol 2011;46:289-96. [PMID: 21350811 DOI: 10.1007/s00535-011-0387-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
242 Lee KT, Lu YW, Wang SN, Chen HY, Chuang SC, Chang WT, Shi HY, Ker CG, Chiu HC. The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. J Surg Oncol 2009;99:343-50. [PMID: 19226530 DOI: 10.1002/jso.21248] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
243 Imaeda M, Ishikawa H, Yoshida Y, Takahashi T, Ohkubo Y, Musha A, Komachi M, Nakazato Y, Nakano T. Long-term pathological and immunohistochemical features in the liver after intraoperative whole-liver irradiation in rats. J Radiat Res 2014;55:665-73. [PMID: 24566720 DOI: 10.1093/jrr/rru005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
244 Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, Kykalos S, Karamouzis MV, Schizas D. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers (Basel) 2020;12:E2859. [PMID: 33020428 DOI: 10.3390/cancers12102859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
245 Pacella CM, Bizzarri G, Francica G, Forlini G, Petrolati A, Valle D, Anelli V, Bianchini A, Nuntis SD, Pacella S, Rossi Z, Osborn J, Stasi R. Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. Journal of Hepatology 2006;44:902-9. [DOI: 10.1016/j.jhep.2006.01.031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
246 Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, Takagi H, Naganuma A, Otsuka T, Takahashi H. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol. 2007;22:518-522. [PMID: 17376044 DOI: 10.1111/j.1440-1746.2007.04844.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
247 Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794-802. [PMID: 22634125 DOI: 10.1016/j.jhep.2012.05.007] [Cited by in Crossref: 374] [Cited by in F6Publishing: 340] [Article Influence: 41.6] [Reference Citation Analysis]
248 Morris-stiff G, Gomez D, de Liguori Carino N, Prasad K. Surgical management of hepatocellular carcinoma: Is the jury still out? Surgical Oncology 2009;18:298-321. [DOI: 10.1016/j.suronc.2008.08.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
249 Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063. [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
250 Cho YB, Lee KU, Suh KS, Kim YJ, Yoon JH, Lee HS, Hahn S, Park BJ. Hepatic resection compared to percutaneous ethanol injection for small hepatocellular carcinoma using propensity score matching. J Gastroenterol Hepatol. 2007;22:1643-1649. [PMID: 17845692 DOI: 10.1111/j.1440-1746.2007.04902.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
251 Zhang Y, Xu H, Chi X, Fan Y, Shi Y, Niu J. High level of serum Cripto-1 in hepatocellular carcinoma, especially with hepatitis B virus infection. Medicine (Baltimore) 2018;97:e11781. [PMID: 30170372 DOI: 10.1097/MD.0000000000011781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
252 Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37-51. [PMID: 18039202 DOI: 10.1111/j.1872-034x.2007.00216.x] [Cited by in Crossref: 211] [Cited by in F6Publishing: 79] [Article Influence: 21.1] [Reference Citation Analysis]
253 Kaido T. Analysis of Randomized Controlled Trials on Hepatopancreatic Surgery. Dig Dis Sci 2006;51:1761-6. [DOI: 10.1007/s10620-006-9219-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
254 Nakayama H, Sugahara S, Tokita M, Fukuda K, Mizumoto M, Abei M, Shoda J, Sakurai H, Tsuboi K, Tokuuye K. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer. 2009;115:5499-5506. [PMID: 19645024 DOI: 10.1002/cncr.24619] [Cited by in Crossref: 89] [Cited by in F6Publishing: 66] [Article Influence: 8.1] [Reference Citation Analysis]
255 Yoo HJ, Lee JM, Lee JY, Kim SH, Kim SJ, Han JK, Choi BI. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver. Invest Radiol. 2009;44:800-807. [PMID: 19838119 DOI: 10.1097/rli.0b013e3181bc271d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
256 Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007;5:508-12. [PMID: 17382601 DOI: 10.1016/j.cgh.2007.01.014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
257 Zhu Q, Qiao G, Xu C, Yu X, Zhao J, Yu Z, Hu M, Yang Y, Wang L, Lu M, Hu F, Cheng Z, Zhou J. Conditional survival in patients with spontaneous tumor rupture of hepatocellular carcinoma after partial hepatectomy: a propensity score matching analysis. HPB (Oxford) 2019;21:722-30. [PMID: 30389432 DOI: 10.1016/j.hpb.2018.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
258 Kaneko H. Laparoscopic hepatectomy: indications and outcomes. J Hepatobiliary Pancreat Surg. 2005;12:438-443. [PMID: 16365815 DOI: 10.1007/s00534-005-1028-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
259 Huang J, Zhang Y, Peng Z, Gao H, Xu L, Jiao LR, Chen M. A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol. 2013;139:1709-1719. [PMID: 23982274 DOI: 10.1007/s00432-013-1497-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
260 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 255] [Article Influence: 30.3] [Reference Citation Analysis]
261 Benzoni E, Lorenzin D, Favero A, Adani G, Baccarani U, Molaro R, Zompicchiatti A, Saccomano E, Avellini C, Bresadola F, Uzzau A. Liver Resection for Hepatocellular Carcinoma: a Multivariate Analysis of Factors Associated with Improved Prognosis. the Role of Clinical, Pathological and Surgical Related Factors. Tumori 2007;93:264-8. [DOI: 10.1177/030089160709300306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
262 Farrell C, Halpen A, Cross TJ, Richardson PD, Johnson P, Joekes EC. Ultrasound surveillance for hepatocellular carcinoma: service evaluation of a radiology-led recall system in a tertiary-referral centre for liver diseases in the UK. Clin Radiol. 2017;72:338.e11-338.e17. [PMID: 28041651 DOI: 10.1016/j.crad.2016.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
263 Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol. 2012;39:486-492. [PMID: 22846865 DOI: 10.1053/j.seminoncol.2012.05.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 7.8] [Reference Citation Analysis]
264 Howard JH, Tzeng CD, Smith JK, Eckhoff DE, Bynon JS, Wang T, Arnoletti JP, Heslin MJ. Radiofrequency Ablation for Unresectable Tumors of the Liver. The American Surgeon 2008;74:594-601. [DOI: 10.1177/000313480807400705] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
265 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
266 Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol. 2011;46:1418-1426. [PMID: 21845378 DOI: 10.1007/s00535-011-0452-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
267 Ukawa S, Okada E, Nakamura K, Hirata M, Nagai A, Matsuda K, Yamagata Z, Kamatani Y, Ninomiya T, Kiyohara Y, Muto K, Kubo M, Nakamura Y, Tamakoshi A; BioBank Japan Cooperative Hospital Group. Characteristics of patients with liver cancer in the BioBank Japan project. J Epidemiol 2017;27:S43-8. [PMID: 28214185 DOI: 10.1016/j.je.2016.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
268 Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, Wang K, Pan H. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:193-200. [PMID: 24224779 DOI: 10.1111/jgh.12441] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 10.4] [Reference Citation Analysis]
269 Wong R, Frenette C, Gish R. Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am. 2011;40:599-610. [PMID: 21893276 DOI: 10.1016/j.gtc.2011.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
270 Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, Isaji S, Shiraki K, Fuke H, Uemoto S. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology. 2008;247:260-266. [PMID: 18305190 DOI: 10.1148/radiol.2471070818] [Cited by in Crossref: 132] [Cited by in F6Publishing: 114] [Article Influence: 10.2] [Reference Citation Analysis]
271 Toyama T, Hiramatsu N, Yakushijin T, Oze T, Nakanishi F, Yasumaru M, Mochizuki K, Kanto T, Takehara T, Kasahara A. A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution. J Clin Gastroenterol. 2008;42:317-322. [PMID: 18223490 DOI: 10.1097/mcg.0b013e3180ebe790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
272 Wang N, Zhang D, Zhao W, Fang G, Shi Y, Duan M. Clinical application of an enzyme-linked immunosorbent assay detecting hepatoma-specific γ-glutamyltransferase. Hepatology Research 2009;39:979-87. [DOI: 10.1111/j.1872-034x.2009.00538.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
273 Xing X, Huang Y, Wang S, Chi M, Zeng Y, Chen L, Li L, Zeng J, Lin M, Han X, Liu X, Liu J. Comparative analysis of primary hepatocellular carcinoma with single and multiple lesions by iTRAQ-based quantitative proteomics. Journal of Proteomics 2015;128:262-71. [DOI: 10.1016/j.jprot.2015.08.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
274 Teratani T, Ishikawa T, Shiratori Y, Shiina S, Yoshida H, Imamura M, Obi S, Sato S, Hamamura K, Omata M. Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. Cancer. 2002;95:816-823. [PMID: 12209726 DOI: 10.1002/cncr.10735] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
275 Choi M, Philip PA. Liver-directed therapies for hepatocellular cancer. Community Oncology 2007;4:571-5. [DOI: 10.1016/s1548-5315(11)70037-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
276 Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908-1916. [PMID: 18549877 DOI: 10.1053/j.gastro.2008.02.091] [Cited by in Crossref: 435] [Cited by in F6Publishing: 419] [Article Influence: 33.5] [Reference Citation Analysis]
277 Wang BW, Mok KT, Liu SI, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC. Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma? J Formos Med Assoc. 2008;107:616-626. [PMID: 18678545 DOI: 10.1016/s0929-6646(08)60179-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
278 Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21:8478-8491. [PMID: 26229392 DOI: 10.3748/wjg.v21.i28.8478] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 84] [Article Influence: 18.8] [Reference Citation Analysis]
279 Ansari MS, Tanaka T, Laroia ST, Sun S. Feasibility of Hepatology-Directed Microwave Ablation in Management of Hepatocellular Carcinoma in North America: A Pilot Project. Ann Hepatol 2019;18:11-3. [PMID: 31113579 DOI: 10.5604/01.3001.0012.7855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
280 Yang A, Zhang P, Sun Z, Liu X, Zhang X, Liu X, Wang D, Meng Z. Lysionotin induces apoptosis of hepatocellular carcinoma cells via caspase-3 mediated mitochondrial pathway. Chem Biol Interact 2021;344:109500. [PMID: 33989594 DOI: 10.1016/j.cbi.2021.109500] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
282 Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535-1547. [PMID: 16696801 DOI: 10.1111/j.1365-2036.2006.02932.x] [Cited by in Crossref: 250] [Cited by in F6Publishing: 216] [Article Influence: 16.7] [Reference Citation Analysis]
283 Obed A, Tsui TY, Schnitzbauer AA, Obed M, Schlitt HJ, Becker H, Lorf T. Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg 2008;393:141-7. [PMID: 18043937 DOI: 10.1007/s00423-007-0250-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
284 Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li MLY, Tam KH, Lam CT, Poon RTP, Fan ST. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008;47:919-28. [DOI: 10.1002/hep.22082] [Cited by in Crossref: 251] [Cited by in F6Publishing: 228] [Article Influence: 19.3] [Reference Citation Analysis]
285 Varela M, Sala M, Llovet JM, Bruix J. Natural history and prognostic prediction of patients with hepatocellular carcinoma: REVIEW: NATURAL HISTORY AND PROGNOSTIC PREDICTION. Alimentary Pharmacology & Therapeutics 2003;17:98-102. [DOI: 10.1046/j.1365-2036.17.s2.11.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
286 Nagahashi M, Matsuda Y, Moro K, Tsuchida J, Soma D, Hirose Y, Kobayashi T, Kosugi SI, Takabe K, Komatsu M. DNA damage response and sphingolipid signaling in liver diseases. Surg Today. 2015; Oct 29; Epub ahead of print. [PMID: 26514817 DOI: 10.1007/s00595-015-1270-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
287 Bertero L, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U, Papotti M, Cassoni P. Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why? Virchows Arch 2018;472:519-31. [PMID: 29209757 DOI: 10.1007/s00428-017-2276-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
288 Yamanaka J, Saito S, Fujimoto J. Impact of preoperative planning using virtual segmental volumetry on liver resection for hepatocellular carcinoma. World J Surg. 2007;31:1249-1255. [PMID: 17440774 DOI: 10.1007/s00268-007-9020-8] [Cited by in Crossref: 88] [Cited by in F6Publishing: 66] [Article Influence: 6.3] [Reference Citation Analysis]
289 Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, Khorana AA. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res. 2008;122:299-306. [PMID: 18045666 DOI: 10.1016/j.thromres.2007.10.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
290 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
291 Sia KC, Huynh H, Chinnasamy N, Hui KM, Lam PY. Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging. Gene Ther 2012;19:532-42. [PMID: 21918545 DOI: 10.1038/gt.2011.131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
292 Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, Kondo F, Saisho H. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol. 2005;43:458-464. [PMID: 16005538 DOI: 10.1016/j.jhep.2005.03.033] [Cited by in Crossref: 129] [Cited by in F6Publishing: 108] [Article Influence: 8.1] [Reference Citation Analysis]
293 Tanaka K, Kojima T, Hiraguchi E, Hashida H, Noji T, Hirano S. Laparoscopy-Guided Transthoracic Transdiaphragmatic Radiofrequency Ablation for Hepatic Tumors Located Beneath the Diaphragm. J Laparoendosc Adv Surg Tech A 2016;26:180-4. [PMID: 26859794 DOI: 10.1089/lap.2015.0380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
294 Moon D, Lee S, Hwang S. Liver Transplantation for Hepatocellular Carcinoma: Single Nodule with Child-Pugh Class A Sized Less than 3 cm. Dig Dis 2007;25:320-8. [DOI: 10.1159/000106912] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
295 Shehta A, Han H, Yoon Y, Cho JY, Choi Y. Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: 10-year single-center experience. Surg Endosc 2016;30:638-48. [DOI: 10.1007/s00464-015-4253-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
296 Murillo A, Artigas V, González JA, Gallego A, Montserrat E, Rodriguez M, Trías M. Resección hepática por hepatocarcinoma: estudio comparativo entre pacientes menores y mayores de 70 años. Cirugía Española 2013;91:224-30. [DOI: 10.1016/j.ciresp.2012.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
297 Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151-1156. [PMID: 16009687 DOI: 10.1136/gut.2004.045203] [Cited by in Crossref: 422] [Cited by in F6Publishing: 359] [Article Influence: 26.4] [Reference Citation Analysis]
298 Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, Kenjo M, Murakami Y, Honda Y, Kakizawa H, Awai K, Chayama K, Nagata Y. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 2015;45:378-86. [PMID: 24849379 DOI: 10.1111/hepr.12359] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
299 Handa T, Imai Y, Sugawara K, Chikayama T, Nakazawa M, Ando S, Hamaoka K, Inao M, Nakayama N, Mochida S. Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin: TACE for HCC with miriplatin vs epirubicin. Hepatol Res 2014;44:1072-80. [DOI: 10.1111/hepr.12225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
300 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015;7:362-76. [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 11.7] [Reference Citation Analysis]
301 Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Suzuki T, Shimamura T, Furukawa H, Matsushita M, Todo S. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol. 2009;16:1560-1571. [PMID: 19259739 DOI: 10.1245/s10434-009-0407-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 6.0] [Reference Citation Analysis]
302 Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29:130-143. [PMID: 18061252 DOI: 10.1016/j.mam.2007.09.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 4.7] [Reference Citation Analysis]
303 Sato M, Tateishi R, Yasunaga H, Matsui H, Fushimi K, Ikeda H, Yatomi Y, Koike K. In-hospital mortality associated with transcatheter arterial embolization for treatment of hepatocellular carcinoma in patients on hemodialysis for end stage renal disease: a matched-pair cohort study using a nationwide database. BJR Open. 2019;1:20190004. [PMID: 33178938 DOI: 10.1259/bjro.20190004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
304 Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ookawa A, Hashii H, Kanemoto A, Moritake T, Tohno E, Tsuboi K, Sakae T, Sakurai H. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys. 2011;81:1039-1045. [PMID: 20888707 DOI: 10.1016/j.ijrobp.2010.07.015] [Cited by in Crossref: 102] [Cited by in F6Publishing: 77] [Article Influence: 9.3] [Reference Citation Analysis]
305 Ueno M, Hayami S, Shigekawa Y, Kawai M, Hirono S, Okada K, Tamai H, Shingaki N, Mori Y, Ichinose M, Yamaue H. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ⩽5 cm: Cohort study based on serum HCC markers. Journal of Hepatology 2015;63:1352-9. [DOI: 10.1016/j.jhep.2015.07.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
306 Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e447-e453. [PMID: 21645977 DOI: 10.1016/j.ijrobp.2011.04.011] [Cited by in Crossref: 262] [Cited by in F6Publishing: 218] [Article Influence: 26.2] [Reference Citation Analysis]
307 Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 2005;89:391-409. [PMID: 15656932 DOI: 10.1016/j.mcna.2004.08.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
308 Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C virus infection with hepatocellular carcinoma: not a controversial indication for liver transplantation. Transplantation. 2004;78:580-583. [PMID: 15446318 DOI: 10.1097/01.tp.0000129797.30999.69] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
309 Guo X, Xu Y, Wang X, Lin F, Wu H, Duan J, Xiong Y, Han X, Baklaushev VP, Xiong S, Chekhonin VP, Peltzer K, Wang G, Zhang C. Advanced Hepatocellular Carcinoma with Bone Metastases: Prevalence, Associated Factors, and Survival Estimation. Med Sci Monit 2019;25:1105-12. [PMID: 30739123 DOI: 10.12659/MSM.913470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
310 Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1031-1036. [PMID: 26647219 DOI: 10.1111/jgh.13250] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 27.3] [Reference Citation Analysis]
311 Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475-4483. [PMID: 21437884 DOI: 10.1002/cncr.25960] [Cited by in Crossref: 228] [Cited by in F6Publishing: 186] [Article Influence: 22.8] [Reference Citation Analysis]
312 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 671] [Article Influence: 62.2] [Reference Citation Analysis]
313 Hong YJ, Kim SH, Choi GH, Kim KS, Choi JS. Long-term outcome after liver resection and clinicopathological features in patients with small hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2011;15:199-205. [PMID: 26421040 DOI: 10.14701/kjhbps.2011.15.4.199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
314 Chiba N, Yokozuka K, Ochiai S, Gunji T, Okihara M, Sano T, Tomita K, Tsutsui R, Kawachi S. The diagnostic value of 99m-Tc GSA scintigraphy for liver function and remnant liver volume in hepatic surgery: a retrospective observational cohort study in 27 patients. Patient Saf Surg 2018;12:15. [PMID: 29881460 DOI: 10.1186/s13037-018-0161-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
315 Bonin S, Pascolo L, Crocé LS, Stanta G, Tiribelli C. Gene Expression of ABC Proteins in Hepatocellular Carcinoma, Perineoplastic Tissue, and Liver Diseases. Mol Med 2002;8:318-25. [DOI: 10.1007/bf03402158] [Cited by in Crossref: 37] [Article Influence: 1.9] [Reference Citation Analysis]
316 Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiro M, Ichida T, Arii S. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:884-892. [PMID: 17048053 DOI: 10.1007/s00535-006-1878-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
317 Wei H, Huang J, Yang J, Zhang X, Lin L, Xue E, Chen Z. Ultrasound exposure improves the targeted therapy effects of galactosylated docetaxel nanoparticles on hepatocellular carcinoma xenografts. PLoS One. 2013;8:e58133. [PMID: 23469265 DOI: 10.1371/journal.pone.0058133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
318 Li X, Han Z, Cheng Z, Yu J, Yu X, Liang P. Clinical significance of preoperative platelet-to-lymphocyte ratio in recurrent hepatocellular carcinoma after thermal ablation: A retrospective analysis. International Journal of Hyperthermia 2015;31:758-63. [DOI: 10.3109/02656736.2015.1068958] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
319 Wang XL, Li K, Su ZZ, Huang ZP, Wang P, Zheng RQ. Assessment of radiofrequency ablation margin by MRI-MRI image fusion in hepatocellular carcinoma. World J Gastroenterol 2015;21:5345-51. [PMID: 25954109 DOI: 10.3748/wjg.v21.i17.5345] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
320 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
321 Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S, Koike K. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol 2012;47:1125-33. [DOI: 10.1007/s00535-012-0569-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 8.0] [Reference Citation Analysis]
322 Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Radiology. 2011;259:286-295. [PMID: 21330557 DOI: 10.1148/radiol.10101072] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
323 Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. Clin Drug Investig 2012;32 Suppl 2:37-51. [PMID: 22873626 DOI: 10.1007/BF03265495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
324 Masaki T, Morishita A, Kurokohchi K, Kuriyama S. Multidisciplinary treatment of patients with hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;6:1377-84. [DOI: 10.1586/14737140.6.10.1377] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
325 Jia D, Lu W, Zhang X, Cai G, Teng L, Wang X, Zhang M, Zeng Y, Liang C, Wang D. Calf Spleen Extractive Injection (CSEI), a small peptides enriched extraction, induces human hepatocellular carcinoma cell apoptosis via ROS/MAPKs dependent mitochondrial pathway. J Pharmacol Sci 2016;132:122-30. [PMID: 28314430 DOI: 10.1016/j.jphs.2016.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
326 Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY. Surgery for Hepatocellular Carcinoma: Does It Improve Survival? Ann Surg Oncol 2004;11:298-303. [DOI: 10.1245/aso.2004.03.042] [Cited by in Crossref: 64] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
327 Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17-S26. [PMID: 15508082 DOI: 10.1053/j.gastro.2004.09.012] [Cited by in Crossref: 221] [Cited by in F6Publishing: 215] [Article Influence: 13.0] [Reference Citation Analysis]
328 Li YF, Yuan YY, Zhang YM, Zhao N, Zhang Q, Meng FX, Gao RP, Yu BF, Zhang YH, Guo R, Wang HL, Xie J, Xu J, Qin Q, Dong XS. HSVtk/GCV system on hepatoma carcinoma cells: Construction of the plasmid pcDNA3.1‑pAFP-TK and targeted killing effect. Mol Med Rep 2017;16:764-72. [PMID: 28560395 DOI: 10.3892/mmr.2017.6657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
329 Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805. [PMID: 19387322 DOI: 10.1097/sla.0b013e3181a38eb5] [Cited by in Crossref: 185] [Cited by in F6Publishing: 75] [Article Influence: 15.4] [Reference Citation Analysis]
330 Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Science 2009;100:1-8. [DOI: 10.1111/j.1349-7006.2008.01006.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
331 Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
332 Hiraoka A, Kumagi T, Hirooka M, Uehara T, Kurose K, Iuchi H, Hiasa Y, Matsuura B, Michitaka K, Kumano S, Tanaka H, Yamashita Y, Horiike N, Mochizuki T, Onji M. Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J Gastroenterol 2006;12:2075-9. [PMID: 16610060 DOI: 10.3748/wjg.v12.i13.2075] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
333 Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S. Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011). Hepatol Res 2021;51:355-405. [PMID: 33382910 DOI: 10.1111/hepr.13612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
334 Yang ZF, Poon RT. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken). 2008;291:721-734. [PMID: 18484619 DOI: 10.1002/ar.20668] [Cited by in Crossref: 112] [Cited by in F6Publishing: 102] [Article Influence: 8.6] [Reference Citation Analysis]
335 Kammula US. Predicting Outcomes After Percutaneous Ethanol Injection for Small Hepatocellular Cancer: . The Cancer Journal 2006;12:175-7. [DOI: 10.1097/00130404-200605000-00003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
336 Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot F, Roumilhac D, Canva V, Paris J, Chaput J, Naveau S. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma: META-ANALYSIS: ADJUVANT THERAPY AFTER CURATIVE LIVER RESECTION FOR HCC. Alimentary Pharmacology & Therapeutics 2003;17:1247-61. [DOI: 10.1046/j.1365-2036.2003.01580.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 4.2] [Reference Citation Analysis]
337 Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol. 2013;8:250. [PMID: 24160944 DOI: 10.1186/1748-717x-8-250] [Cited by in Crossref: 124] [Cited by in F6Publishing: 50] [Article Influence: 15.5] [Reference Citation Analysis]
338 Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56:412-418. [PMID: 21756858 DOI: 10.1016/j.jhep.2011.05.020] [Cited by in Crossref: 182] [Cited by in F6Publishing: 181] [Article Influence: 18.2] [Reference Citation Analysis]
339 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 552] [Article Influence: 44.3] [Reference Citation Analysis]
340 Ochiai T, Sonoyama T, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Ueda Y, Otsuji E, Itoi H, Hagiwara A. Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. J Cancer Res Clin Oncol. 2004;130:197-202. [PMID: 14770307 DOI: 10.1007/s00432-003-0533-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
341 Graf D, Vallböhmer D, Knoefel WT, Kröpil P, Antoch G, Sagir A, Häussinger D. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25:430-437. [PMID: 24666568 DOI: 10.1016/j.ejim.2014.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
342 Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Nakamura N, Ito K, Miki Y, Inazawa J, Tanaka H, Arii S. Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery 2010;147:405-14. [DOI: 10.1016/j.surg.2009.09.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
343 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
344 Ochiai T, Sonoyama T, Kikuchi S, Okayama T, Konishi H, Kitagawa M, Tagi T, Ueda Y, Otsuji E. Anatomic wide hepatectomy for treatment of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2007;133:563-569. [PMID: 17457610 DOI: 10.1007/s00432-007-0205-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
345 Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003;237:171-179. [PMID: 12560774 DOI: 10.1097/01.sla.0000048443.71734.bf] [Cited by in Crossref: 127] [Cited by in F6Publishing: 78] [Article Influence: 7.1] [Reference Citation Analysis]
346 Endo Y, Ohta M, Sasaki A, Kai S, Eguchi H, Iwaki K, Shibata K, Kitano S. A comparative study of the long-term outcomes after laparoscopy-assisted and open left lateral hepatectomy for hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2009;19:e171-e174. [PMID: 19851245 DOI: 10.1097/sle.0b013e3181bc4091] [Cited by in Crossref: 68] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
347 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 55] [Article Influence: 8.7] [Reference Citation Analysis]
348 Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F, Dupas B, Martin T, Nouel JF, Schnée M, Montigny P, D'alincourt A, Hamy A, Paineau J, Le Néel J-, Le Borgne J, Galmiche JP. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis: PERCUTANEOUS ETHANOL INJECTION VS. RESECTION IN HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2002;16:1529-38. [DOI: 10.1046/j.1365-2036.2002.01307.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
349 Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Matsushita M, Todo S. The impact of anatomical resection for hepatocellular carcinoma that meets the Milan criteria. J Surg Oncol 2010;101:54-60. [PMID: 19798687 DOI: 10.1002/jso.21414] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
350 Pompili M, Nicolardi E, Abbate V, Miele L, Riccardi L, Covino M, De Matthaeis N, Grieco A, Landolfi R, Rapaccini GL. Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2011;17:3126-32. [PMID: 21912455 DOI: 10.3748/wjg.v17.i26.3126] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
351 Yin X, Lu M. Percutaneous ablation for small hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;3:121-30. [DOI: 10.1586/egh.09.7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
352 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
353 Nakagawa S, Beppu T, Okabe H, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Hayashi H, Sakamoto Y. Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma. Hepatol Res. 2014;44:964-974. [PMID: 24245496 DOI: 10.1111/hepr.12277] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
354 Uchida H, Iwashita Y, Tada K, Saga K, Takayama H, Hirashita T, Endo Y, Ohta M, Inomata M. Laparoscopic liver resection in cirrhotic patients with specific reference to a difficulty scoring system. Langenbecks Arch Surg 2018;403:371-7. [DOI: 10.1007/s00423-018-1671-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
355 Yao X, Yan D, Jiang X, Li X, Zeng H, Liu D, Li H. Dual-phase Cone-beam CT-based Navigation Imaging Significantly Enhances Tumor Detectability and Aids Superselective Transarterial Chemoembolization of Liver Cancer. Acad Radiol. 2018;25:1031-1037. [PMID: 29398432 DOI: 10.1016/j.acra.2017.12.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
356 Theodoropoulos J, Brooks A. Inconsistency in the Management of Patients with Hepatocellular Carcinoma: The Need for a Strict Protocol. The American Surgeon 2011;77:207-14. [DOI: 10.1177/000313481107700223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
357 Lin LW, Lin XD, He YM, Gao SD, Xue ES. Experimental study on ultrasound-guided intratumoral injection of "Star-99" in treatment of hepatocellular carcinoma of nude mice. World J Gastroenterol 2003;9:701-5. [PMID: 12679914 DOI: 10.3748/wjg.v9.i4.701] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
358 Jin YJ, Cho SG, Lee KY, Kim JM, Lee JW. Association between relative liver enhancement on gadoxetic acid enhanced magnetic resonance images and histologic grade of hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e7580. [PMID: 28746206 DOI: 10.1097/MD.0000000000007580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
359 Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura S, Ohnishi H, Kuwaki K, Toshimori J, Hagihara H, Nouso K, Yamamoto K. Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci 2012;57:1092-101. [DOI: 10.1007/s10620-011-1934-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
360 Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003;237:171-179. [PMID: 12560774 DOI: 10.1097/00000658-200302000-00005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
361 Zhang N, Wang L, Chai ZT, Zhu ZM, Zhu XD, Ma DN, Zhang QB, Zhao YM, Wang M, Ao JY, Ren ZG, Gao DM, Sun HC, Tang ZY. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One 2014;9:e115949. [PMID: 25542041 DOI: 10.1371/journal.pone.0115949] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
362 Kang J, Kim M, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung DH, Kim KB, Lee DH, Han CJ, Kim J, Park SC, Kim YH. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization: A single-institution phase 2 trial. Cancer 2012;118:5424-31. [DOI: 10.1002/cncr.27533] [Cited by in Crossref: 196] [Cited by in F6Publishing: 162] [Article Influence: 21.8] [Reference Citation Analysis]
363 Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology. 2010;51:1284-1290. [PMID: 20099299 DOI: 10.1002/hep.23466] [Cited by in Crossref: 171] [Cited by in F6Publishing: 135] [Article Influence: 15.5] [Reference Citation Analysis]
364 Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology 2019;292:390-7. [PMID: 31210614 DOI: 10.1148/radiol.2019190035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
365 Zhou Y, Shi WY, He W, Yan ZW, Liu MH, Chen J, Yang YS, Wang YQ, Chen GQ, Huang Y. FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity. Exp Cell Res 2020;387:111714. [PMID: 31711919 DOI: 10.1016/j.yexcr.2019.111714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
366 Gandhi SJ, Liang X, Ding X, Zhu TC, Ben-Josef E, Plastaras JP, Metz JM, Both S, Apisarnthanarax S. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. Pract Radiat Oncol. 2015;5:209-218. [PMID: 25703530 DOI: 10.1016/j.prro.2015.01.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
367 Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115-S120. [PMID: 14762851 DOI: 10.1002/lt.20034] [Cited by in Crossref: 459] [Cited by in F6Publishing: 411] [Article Influence: 27.0] [Reference Citation Analysis]
368 Bester L, Meteling B, Boshell D, Chua TC, Morris DL. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature: Embolisation therapies in liver cancer. Journal of Medical Imaging and Radiation Oncology 2014;58:341-52. [DOI: 10.1111/1754-9485.12163] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
369 Kasugai H, Osaki Y, Oka H, Kudo M, Seki T. Severe Complications of Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: An Analysis of 3,891 Ablations in 2,614 Patients. Oncology 2007;72:72-5. [DOI: 10.1159/000111710] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
370 Kanematsu T, Furui J, Yanaga K, Okudaira S, Shimada M, Shirabe K. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery. 2002;131:S153-S158. [PMID: 11821803 DOI: 10.1067/msy.2002.119497] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
371 Nanashima A, Masuda J, Miuma S, Sumida Y, Nonaka T, Tanaka K, Hidaka S, Sawai T, Nagayasu T. Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score. World J Gastroenterol 2008;14:58-63. [PMID: 18176962 DOI: 10.3748/wjg.14.58] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
372 Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469. [PMID: 16890600 DOI: 10.1053/j.gastro.2006.05.021] [Cited by in Crossref: 524] [Cited by in F6Publishing: 470] [Article Influence: 34.9] [Reference Citation Analysis]
373 Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2020;50:15-46. [PMID: 31655492 DOI: 10.1111/hepr.13438] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 51.0] [Reference Citation Analysis]
374 Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J; for the Barcelona Cly'nic Liver Cancer (BCLC) Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-60. [DOI: 10.1002/hep.20465] [Cited by in Crossref: 330] [Cited by in F6Publishing: 281] [Article Influence: 19.4] [Reference Citation Analysis]
375 Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis. 2013;45:510-515. [PMID: 23218990 DOI: 10.1016/j.dld.2012.10.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
376 Choi SH, Choi GH, Kim SU, Park JY, Joo DJ, Ju MK, Kim MS, Choi JS, Han KH, Kim SI. Role of surgical resection for multiple hepatocellular carcinomas. World J Gastroenterol. 2013;19:366-374. [PMID: 23372359 DOI: 10.3748/wjg.v19.i3.366] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
377 El Sayed I, Helmy MW, El-Abhar HS. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. Life Sci 2018;213:248-57. [PMID: 30292831 DOI: 10.1016/j.lfs.2018.10.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
378 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
379 Facciuto ME, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, Moorthy CR, Bentley-Hibbert S, Rodriguez-Davalos M, Wolf DC. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol. 2012;105:692-698. [PMID: 21960321 DOI: 10.1002/jso.22104] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
380 Shiina S. Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol 2009;44:122-31. [DOI: 10.1007/s00535-008-2263-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
381 Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, Li KQ, Jin CB, Xie FL, Su HB. Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology. 2005;235:659-667. [PMID: 15858105 DOI: 10.1148/radiol.2352030916] [Cited by in Crossref: 167] [Cited by in F6Publishing: 144] [Article Influence: 10.4] [Reference Citation Analysis]
382 Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH, Kanwal F, El-Serag HB. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858-1868. [PMID: 23359313 DOI: 10.1002/hep.26287] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
383 Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153-166. [PMID: 18242515 DOI: 10.1016/j.ccr.2008.01.013] [Cited by in Crossref: 835] [Cited by in F6Publishing: 751] [Article Influence: 64.2] [Reference Citation Analysis]
384 Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S. Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study. J Gastroenterol. 2014;49:502-510. [PMID: 23543312 DOI: 10.1007/s00535-013-0791-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
385 Tashiro H, Aikata H, Waki K, Amano H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Chayama K, Asahara T, Ohdan H. Treatment strategy for early hepatocellular carcinomas: Comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol 2011;104:3-9. [DOI: 10.1002/jso.21745] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
386 Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2012;27:51-58. [PMID: 22004366 DOI: 10.1111/j.1440-1746.2011.06947.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 6.8] [Reference Citation Analysis]
387 Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, Hidaka S, Tanaka K, Sawai T, Yasutake T, Nagayasu T, Omagari K, Mine M. Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol 2006;41:250-6. [DOI: 10.1007/s00535-005-1751-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
388 Kim JM, Kang TW, Kwon CH, Joh JW, Ko JS, Park JB, Rhim H, Lee JH, Kim SJ, Paik SW. Single hepatocellular carcinoma ≤ 3 cm in left lateral segment: liver resection or radiofrequency ablation? World J Gastroenterol 2014;20:4059-65. [PMID: 24744596 DOI: 10.3748/wjg.v20.i14.4059] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
389 Yamanaka J, Okada T, Saito S, Kondo Y, Yoshida Y, Suzumura K, Hirano T, Iimuro Y, Fujimoto J. Minimally invasive laparoscopic liver resection: 3D MDCT simulation for preoperative planning. J Hepatobiliary Pancreat Surg. 2009;16:808-815. [PMID: 19466379 DOI: 10.1007/s00534-009-0112-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
390 Ercolani G, Grazi GL, Ravaioli M, Grigioni WF, Cescon M, Gardini A, Del Gaudio M, Cavallari A. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg. 2004;239:202-209. [PMID: 14745328 DOI: 10.1097/01.sla.0000109154.00020.e0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 6.2] [Reference Citation Analysis]
391 Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:530-536. [PMID: 23216217 DOI: 10.1111/jgh.12087] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
392 Chiba N, Shimazu M, Takano K, Oshima G, Tomita K, Sano T, Okihara M, Ozawa Y, Hikita K, Gunji T, Abe Y, Koizumi K, Kawachi S. Predicting hepatic failure with a new diagnostic technique by preoperative liver scintigraphy and computed tomography: a pilot study in 123 patients undergoing liver resection. Patient Saf Surg 2017;11:29. [PMID: 29270223 DOI: 10.1186/s13037-017-0143-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
393 Park TY, Na YC, Lee WH, Kim JH, Chang WS, Jung HH, Chang JH, Chang JW, Park YG. Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection vs. Gamma Knife Radiosurgery vs. Whole Brain Radiation Therapy. Brain Tumor Res Treat 2013;1:78-84. [PMID: 24904896 DOI: 10.14791/btrt.2013.1.2.78] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
394 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
395 Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347:415-419. [PMID: 24759379 DOI: 10.1097/maj.0000000000000200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
396 Wakatsuki T, Obara K, Irisawa A, Sakamoto H, Kuwana T, Takiguchi F, Saito A, Shishido H, Hikichi T, Oyama H, Shibukawa G, Takagi T, Yamamoto G, Imamura H, Takahashi Y, Sato A, Sato M, Kasukawa R, Ohira H. Analysis of prognostic factors in patients with gastric varices after endoscopic treatment. Dig Endosc 2009;21:232-8. [PMID: 19961521 DOI: 10.1111/j.1443-1661.2009.00898.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
397 Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005;31:331-347. [PMID: 15837037 DOI: 10.1016/j.ejso.2004.10.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 5.8] [Reference Citation Analysis]
398 Tanaka S, Arii S. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int J Clin Oncol 2010;15:235-41. [DOI: 10.1007/s10147-010-0083-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
399 Jiang L, Liao A, Wen T, Yan L, Li B, Yang J. Living donor liver transplantation or resection for Child-Pugh A hepatocellular carcinoma patients with multiple nodules meeting the Milan criteria. Transpl Int. 2014;27:562-569. [PMID: 24606007 DOI: 10.1111/tri.12297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
400 Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y. Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey. Journal of Hepatology 2013;58:724-9. [DOI: 10.1016/j.jhep.2012.11.009] [Cited by in Crossref: 208] [Cited by in F6Publishing: 176] [Article Influence: 26.0] [Reference Citation Analysis]
401 Signoriello S, Annunziata A, Lama N, Signoriello G, Chiodini P, De Sio I, Daniele B, Di Costanzo GG, Calise F, Olivieri G, Castaldo V, Lanzetta R, Piai G, Marone G, Visconti M, Fusco M, Di Maio M, Perrone F, Gallo C, Gaeta GB. Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. ScientificWorldJournal. 2012;2012:564706. [PMID: 22654628 DOI: 10.1100/2012/564706] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
402 Guo RP, Zhong C, Shi M, Zhang CQ, Wei W, Zhang YQ, Li JQ. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:547-555. [PMID: 16763805 DOI: 10.1007/s00432-006-0097-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
403 Thein H, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ. Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort: HCC survival in people with hepatitis B or C. Hepatology Research 2012;42:1175-86. [DOI: 10.1111/j.1872-034x.2012.01037.x] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
404 Lopez PM, Patel P, Uva P, Villanueva A, Llovet JM. Current management of liver cancer. European Journal of Cancer Supplements 2007;5:444-6. [DOI: 10.1016/s1359-6349(07)70093-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
405 Nanashima A, Tobinaga S, Kunizaki M, Miuma S, Taura N, Takeshita H, Hidaka S, Sawai T, Nakao K, Nagayasu T. Strategy of treatment for hepatocellular carcinomas with vascular infiltration in patients undergoing hepatectomy. J Surg Oncol 2010;101:557-63. [PMID: 20213729 DOI: 10.1002/jso.21534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
406 Xiaoying W, Han Z, Yu W. Glycyrrhiza glabra (Licorice). Sustained Energy for Enhanced Human Functions and Activity. Elsevier; 2017. pp. 231-50. [DOI: 10.1016/b978-0-12-805413-0.00014-4] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
407 Ishikawa H, Nakata K, Mawatari F, Ueki T, Tsuruta S, Ido A, Nakao K, Kato Y, Ishii N, Eguchi K. Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter. Biochem Biophys Res Commun. 2001;287:1034-1040. [PMID: 11573968 DOI: 10.1006/bbrc.2001.5684] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
408 Nakahara H, Itamoto T, Katayama K, Ohdan H, Hino H, Ochi M, Tashiro H, Asahara T. Indication of Hepatectomy for Cirrhotic Patients with Hepatocellular Carcinoma Classified as Child-Pugh Class B. World J Surg 2005;29:734-8. [DOI: 10.1007/s00268-005-7750-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
409 Tamai T, Oshige A, Tabu K, Tabu E, Ijyuin S, Sakae H, Onishi H, Muromachi K, Saisyoji A, Oda K, Kumagai K, Mawatari S, Moriuchi A, Sakurai K, Hori T, Ido A. Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma. Oncol Lett. 2017;14:3199-3206. [PMID: 28927066 DOI: 10.3892/ol.2017.6476] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
410 Zavaglia C, Corso R, Rampoldi A, Vinci M, Belli LS, Vangeli M, Solcia M, Castoldi C, Prisco C, Vanzulli A, Pinzello G. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure?: . European Journal of Gastroenterology & Hepatology 2008;20:196-201. [DOI: 10.1097/meg.0b013e3282f1cc4a] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
411 Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer 2003;39:2150-64. [PMID: 14522372 DOI: 10.1016/s0959-8049(03)00553-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
412 Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W, Bakhtiar Ui Islam SM. Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma. Clin Mol Hepatol 2016;22:267-71. [PMID: 27184470 DOI: 10.3350/cmh.2015.0017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
413 Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology 2010;138:52-64. [DOI: 10.1053/j.gastro.2009.09.006] [Cited by in Crossref: 650] [Cited by in F6Publishing: 544] [Article Influence: 59.1] [Reference Citation Analysis]
414 Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol. 2011;46:289-296. [PMID: 21350811 DOI: 10.1007/500535-011-0387-9] [Reference Citation Analysis]
415 Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Opelz G, Mehrabi A. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. Br J Cancer. 2015;113:756-762. [PMID: 26270232 DOI: 10.1038/bjc.2015.227] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
416 Takayasu K, Muramatsu Y, Mizuguchi Y, Okusaka T, Shimada K, Takayama T, Sakamoto M. CT Evaluation of the Progression of Hypoattenuating Nodular Lesions in Virus-Related Chronic Liver Disease. American Journal of Roentgenology 2006;187:454-63. [DOI: 10.2214/ajr.05.0705] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
417 Qiao G, Li J, Huang A, Yan Z, Lau WY, Shen F. Artificial neural networking model for the prediction of post-hepatectomy survival of patients with early hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:2014-2020. [PMID: 24989634 DOI: 10.1111/jgh.12672] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
418 Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, Arisawa K, Ishibashi H, Koga M, Sata M. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer. 2003;98:2671-2677. [PMID: 14669288 DOI: 10.1002/cncr.11839] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
419 Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Kakisaka T, Tsuruga Y, Todo S, Taketomi A. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. World J Surg Oncol. 2012;10:107. [PMID: 22697061 DOI: 10.1186/1477-7819-10-107] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
420 Sherman M, Klein A. AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 2004;40:1465-73. [PMID: 15565604 DOI: 10.1002/hep.20528] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
421 Tan K. Surgery for hepatocellular carcinoma: Surgery for HCC. Journal of Gastroenterology and Hepatology 2002;17:S421-3. [DOI: 10.1046/j.1440-1746.17.s3.38.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
422 Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl. 2006;12:1747-1754. [PMID: 17133591 DOI: 10.1002/lt.21018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
423 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 25] [Article Influence: 0.6] [Reference Citation Analysis]
424 Gerard B, Bleiberg H. Treatment of hepatocarcinoma. Curr Oncol Rep 2004;6:184-91. [PMID: 15066229 DOI: 10.1007/s11912-004-0048-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
425 Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Actual 10-Year Survival After Surgical Microwave Ablation for Hepatocellular Carcinoma: A Single-Center Experience in Japan. Ann Surg Oncol. 2019;26:4126-4133. [PMID: 31359277 DOI: 10.1245/s10434-019-07646-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
426 Dasari BV, Kamarajah SK, Hodson J, Pawlik TM, Vauthey JN, Ma YT, Punia P, Coldham C, Abradelo M, Roberts KJ, Marudanayagam R, Sutcliffe RP, Muiesan P, Mirza DF, Isaac J. Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. HPB (Oxford). 2020;22:383-390. [PMID: 31416786 DOI: 10.1016/j.hpb.2019.07.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
427 Okamoto E, Sato S, Sanchez-Siles AA, Ishine J, Miyake T, Amano Y, Kinoshita Y. Evaluation of virtual CT sonography for enhanced detection of small hepatic nodules: a prospective pilot study. AJR Am J Roentgenol 2010;194:1272-8. [PMID: 20410414 DOI: 10.2214/AJR.08.2294] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
428 Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, Chen MF. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol. 2011;9:114. [PMID: 21958080 DOI: 10.1186/1477-7819-9-114] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
429 Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther. 2008;8:1743-1749. [PMID: 18983234 DOI: 10.1586/14737140.8.11.1743] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
430 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
431 Zhang Z, Shen S. Combined low miRNA-29s is an independent risk factor in predicting prognosis of patients with hepatocellular carcinoma after hepatectomy: A Chinese population-based study. Medicine (Baltimore) 2017;96:e8795. [PMID: 29310356 DOI: 10.1097/MD.0000000000008795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
432 Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S;  Real-Life Practice Experts For Hepatocellular Carcinoma (HCC) (RELPEC) Study Group and The HCC 48 Group (HCC experts from 48 clinics). Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation. Mol Clin Oncol. 2017;6:455-461. [PMID: 28413650 DOI: 10.3892/mco.2017.1192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
433 Takayama T. Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol. 2011;41:447-454. [PMID: 21411469 DOI: 10.1093/jjco/hyr016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
434 Kow AW, Kwon CH, Song S, Shin M, Kim JM, Joh JW. Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma: review of 1222 cases of hepatectomy in a tertiary institution. Ann Surg Oncol. 2012;19:2246-2255. [PMID: 22402812 DOI: 10.1245/s10434-012-2260-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
435 Liu Z, Zhou Y, Zhang P, Qin H. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010;20:130-140. [PMID: 20551807 DOI: 10.1097/sle.0b013e3181d823df] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
436 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
437 Hiraoka A, Michitaka K, Horiike N, Hidaka S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Sogabe I, Ishimaru Y, Kawasaki H, Koizumi Y, Hirooka M, Yamashita Y, Abe M, Hiasa Y, Matsuura B, Onji M. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol. 2010;25:403-407. [PMID: 19929922 DOI: 10.1111/j.1440-1746.2009.06037.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
438 Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-1405. [PMID: 15565571 DOI: 10.1002/hep.20486] [Cited by in Crossref: 243] [Cited by in F6Publishing: 231] [Article Influence: 14.3] [Reference Citation Analysis]
439 Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008;28:1269-77. [PMID: 18808443 DOI: 10.1111/j.1365-2036.2008.03857.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
440 Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin N Am. 2003;12:25-34, viii. [PMID: 12735127 DOI: 10.1016/s1055-3207(02)00077-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
441 Schoppmeyer K, Weis S, Mössner J, Fleig WE. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;3:CD006745. [PMID: 19588401 DOI: 10.1002/14651858.cd006745.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
442 Kow AW, Kwon CH, Song S, Kim JM, Joh JW. Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma in a tertiary institution. Surgery 2015;157:645-53. [PMID: 25794626 DOI: 10.1016/j.surg.2014.07.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
443 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
444 Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31:883. [PMID: 24535607 DOI: 10.1007/s12032-014-0883-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
445 Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009;185:782-788. [PMID: 20013087 DOI: 10.1007/s00066-009-2020-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 6.6] [Reference Citation Analysis]
446 Hasegawa K, Kokudo N. Surgical treatment of hepatocellular carcinoma. Surg Today 2009;39:833-43. [PMID: 19784720 DOI: 10.1007/s00595-008-4024-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
447 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328. [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8] [Cited by in Crossref: 919] [Cited by in F6Publishing: 791] [Article Influence: 61.3] [Reference Citation Analysis]
448 Tremosini S, Reig M, de Lope CR, Forner A, Bruix J. Treatment of early hepatocellular carcinoma: Towards personalized therapy. Dig Liver Dis. 2010;42 Suppl 3:S242-S248. [PMID: 20547310 DOI: 10.1016/s1590-8658(10)60512-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
449 Luo H, Dong Z, Zou J, Zeng Q, Wu D, Liu L. Down-regulation of RhoE is associated with progression and poor prognosis in hepatocellular carcinoma. J Surg Oncol 2012;105:699-704. [PMID: 22213123 DOI: 10.1002/jso.23019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
450 Maeda T, Hong J, Konishi K, Nakatsuji T, Yasunaga T, Yamashita Y, Taketomi A, Kotoh K, Enjoji M, Nakashima H, Tanoue K, Maehara Y, Hashizume M. Tumor ablation therapy of liver cancers with an open magnetic resonance imaging-based navigation system. Surg Endosc 2009;23:1048-53. [PMID: 18813998 DOI: 10.1007/s00464-008-0123-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
451 Ikemoto T, Shimada M, Yamada S. Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation. Hepatol Res. 2017;47:23-30. [PMID: 26990590 DOI: 10.1111/hepr.12705] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
452 Cárdenes HR, Lasley F. Primary Liver Cancer. In: Lo SS, Teh BS, Lu JJ, Schefter TE, editors. Stereotactic Body Radiation Therapy. Berlin: Springer Berlin Heidelberg; 2012. pp. 163-82. [DOI: 10.1007/174_2012_548] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
453 Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-922. [PMID: 17522517 DOI: 10.1097/01.sla.0000254368.65878.da] [Cited by in Crossref: 220] [Cited by in F6Publishing: 212] [Article Influence: 15.7] [Reference Citation Analysis]
454 Kudo M. Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer 2021;10:167-80. [PMID: 34239807 DOI: 10.1159/000516491] [Reference Citation Analysis]
455 Nakai T, Shiraishi O, Kawabe T, Ota H, Nagano H, Shiozaki H. Significance of HBV DNA in the hepatic parenchyma from patients with non-B, non-C hepatocellular carcinoma. World J Surg 2006;30:1338-43. [PMID: 16773264 DOI: 10.1007/s00268-005-0318-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
456 Peng ZW, Liang HH, Chen MS, Zhang YJ, Li JQ, Zhang YQ, Lau WY. Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe. Eur J Surg Oncol 2008;34:166-72. [PMID: 17851020 DOI: 10.1016/j.ejso.2007.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
457 Shindoh J, Vauthey JN. Staging of biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:313-322. [PMID: 24560112 DOI: 10.1016/j.soc.2013.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
458 Izumi N, Asahina Y, Tsuchiya K, Kurosaki M, Nakanishi H, Kitamura T, Uchihara M, Miyake S. Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival. Hepatology Research 2007;37:S254-63. [DOI: 10.1111/j.1872-034x.2007.00193.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
459 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
460 Nara S, Shimada K, Sakamoto Y, Esaki M, Kishi Y, Kosuge T, Ojima H. Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomies. Surgery. 2012;151:526-536. [PMID: 22244181 DOI: 10.1016/j.surg.2011.12.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
461 Liapi E, Georgiades CC, Hong K, Geschwind JF. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007;10:2-11. [PMID: 17980314 DOI: 10.1053/j.tvir.2007.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
462 Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101:796-802. [PMID: 15305412 DOI: 10.1002/cncr.20426] [Cited by in Crossref: 320] [Cited by in F6Publishing: 274] [Article Influence: 18.8] [Reference Citation Analysis]
463 Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002;235:466-86. [PMID: 11923602 DOI: 10.1097/00000658-200204000-00004] [Cited by in Crossref: 300] [Cited by in F6Publishing: 273] [Article Influence: 15.8] [Reference Citation Analysis]
464 Shehta A, Farouk A, Fouad A, Aboelenin A, Elghawalby AN, Said R, Elshobary M, El Nakeeb A. Post-hepatectomy liver failure after hepatic resection for hepatocellular carcinoma: a single center experience. Langenbecks Arch Surg 2021;406:87-98. [PMID: 32778915 DOI: 10.1007/s00423-020-01956-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003;7:1082-1088. [PMID: 14675719 DOI: 10.1097/00000658-200205000-00015] [Cited by in Crossref: 137] [Cited by in F6Publishing: 126] [Article Influence: 8.1] [Reference Citation Analysis]
466 Wakabayashi H, Ushiyama T, Ishimura K, Izuishi K, Karasawa Y, Masaki T, Watanabe S, Kuriyama S, Maeta H. Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions. J Surg Oncol. 2003;82:98-103. [PMID: 12561065 DOI: 10.1002/jso.10203] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
467 Oishi K, Itamoto T, Amano H, Fukuda S, Ohdan H, Tashiro H, Shimamoto F, Asahara T. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol. 2007;95:311-316. [PMID: 17326126 DOI: 10.1002/jso.20661] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
468 Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013;57:1426-35. [PMID: 22576353 DOI: 10.1002/hep.25832] [Cited by in Crossref: 189] [Cited by in F6Publishing: 170] [Article Influence: 23.6] [Reference Citation Analysis]
469 Lu XY, Xi T, Lau WY, Dong H, Xian ZH, Yu H, Zhu Z, Shen F, Wu MC, Cong WM. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol. 2011;137:567-575. [PMID: 20508947 DOI: 10.1007/s00432-010-0909-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
470 Roayaie S, Llovet JM. Liver Transplantation for Hepatocellular Carcinoma: Is Expansion of Criteria Justified? Clinics in Liver Disease 2005;9:315-28. [DOI: 10.1016/j.cld.2004.12.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
471 Kim SH, Choi SB, Lee JG, Kim SU, Park MS, Kim do Y, Choi JS, Kim KS. Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy. J Gastrointest Surg. 2011;15:598-607. [PMID: 21336497 DOI: 10.1007/s11605-011-1452-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
472 Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y. Report of the 19th follow-up survey of primary liver cancer in Japan: 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 2016;46:372-90. [DOI: 10.1111/hepr.12697] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 17.0] [Reference Citation Analysis]
473 Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Nakayama K, Tanaka H, Yamaoka S, Arii S. Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course. Hepatology. 2013;58:218-228. [PMID: 23447025 DOI: 10.1002/hep.26345] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
474 Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M;  Liver Cancer Study Group of Japan. Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey. Ann Surg. 2020;272:145-154. [PMID: 30672806 DOI: 10.1097/sla.0000000000003192] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 16.0] [Reference Citation Analysis]
475 Xu J, Liu L, Tang H. Antiviral therapy for hepatitis B virus-associated hepatocellular carcinoma: Potential to reduce the tumor recurrence rates and/or improve overall survival. Medical Hypotheses 2011;76:457-9. [DOI: 10.1016/j.mehy.2010.12.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
476 Han M, Ji X, Li J, Ge Z, Luo B, Zhou K, Wang Q, Sun X, Zhang W, Li J. Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect. Int J Nanomedicine 2020;15:3433-45. [PMID: 32523342 DOI: 10.2147/IJN.S241448] [Reference Citation Analysis]
477 Yoon YS, Han HS, Cho JY, Yoon CJ, Kim JH. Laparoscopic approach for treatment of multiple hepatocellular carcinomas. Surg Endosc. 2012;26:3133-3140. [PMID: 22538699 DOI: 10.1007/s00464-012-2304-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
478 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3346] [Article Influence: 404.7] [Reference Citation Analysis]
479 Kurimoto A, Yamanaka J, Hai S, Kondo Y, Sueoka H, Ohashi K, Asano Y, Hirano T, Fujimoto J. Parenchyma-preserving hepatectomy based on portal ramification and perfusion of the right anterior section: preserving the ventral or dorsal area. J Hepatobiliary Pancreat Sci 2016;23:158-66. [DOI: 10.1002/jhbp.317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
480 Jin Y, Lee J, Lee OH, Chung HJ, Kim YS, Lee JI, Cho SG, Jeon YS, Lee KY, Ahn S, Shin WY. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion: Recurrent hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1056-64. [DOI: 10.1111/jgh.12507] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
481 Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, Hirasawa K, Koh R, Nihommatsu H, Tanaka K. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007;13:1003-9. [PMID: 17373733 DOI: 10.3748/wjg.v13.i7.1003] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
482 Zhang L, Zhu H, Jin C, Zhou K, Li K, Su H, Chen W, Bai J, Wang Z. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol. 2009;19:437-445. [PMID: 18795303 DOI: 10.1007/s00330-008-1137-0] [Cited by in Crossref: 138] [Cited by in F6Publishing: 100] [Article Influence: 10.6] [Reference Citation Analysis]
483 Zheng T, Xie F, Geng L, Sui CJ, Dai DH, Shen RX, Yan L, Yang JM. Safety and long-term outcomes of anatomic left hepatic trisectionectomy for intermediate and advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2015;30:1015-23. [PMID: 25641605 DOI: 10.1111/jgh.12887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
484 Zhong J, Li L. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis: Adjuvant TACE for participants with HCC. Hepatology Research 2010;40:943-53. [DOI: 10.1111/j.1872-034x.2010.00710.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
485 Hata M, Tokuuye K, Sugahara S, Fukumitsu N, Hashimoto T, Ohnishi K, Nemoto K, Ohara K, Matsuzaki Y, Akine Y. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 2006;107:591-8. [PMID: 16804931 DOI: 10.1002/cncr.22039] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
486 Hsieh A, Kim H, Lim S, Yu D, Jung G. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling. Cancer Letters 2011;300:162-72. [DOI: 10.1016/j.canlet.2010.09.018] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 8.3] [Reference Citation Analysis]
487 Lee CH, Brubaker LM, Gerber DA, Ku YM, Kim YH, Shin SS, Semelka RC. MRI findings of recurrent hepatocellular carcinoma after liver transplantation: preliminary results. J Magn Reson Imaging. 2011;33:1399-1405. [PMID: 21591009 DOI: 10.1002/jmri.22326] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
488 Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, Brunello F, Pinna AD, Giorgio A, Giulini SM, De Sio I, Torzilli G, Fornari F, Capussotti L, Guglielmi A, Piscaglia F, Aldrighetti L, Caturelli E, Calise F, Nuzzo G, Rapaccini GL, Giuliante F. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ⩽3cm. Results of a multicenter Italian survey. Journal of Hepatology 2013;59:89-97. [DOI: 10.1016/j.jhep.2013.03.009] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 20.0] [Reference Citation Analysis]